



UNIVERSITÀ DEGLI STUDI DI CATANIA
DOTTORATO IN BIOLOGIA UMANA E BIOINFORMATICA:
BASI CELLULARI E MOLECOLARI DEL FENOTIPO
XXVIII CICLO
DIPARTIMENTO DI SCIENZE BIOMEDICHE E BIOTECNOLOGICHE

Virulence gene expression of three hypervirulent
S. pyogenes M1T1 and membrane
vesicles isolation

TESI DI DOTTORATO
Dott.ssa Valeria Metoldo

Coordinatore: Chiar.mo Prof. MICHELE PURRELLO

Tutor: Prof.ssa MARIA SANTAGATI

ANNO ACCADEMICO 2014/2015

Table of Contents

1. Introduction	p.1
1.1 <i>Streptococcus pyogenes</i>	p.3
1.1.1 Classification of GAS	p.3
1.1.2 GAS Surface	p.5
1.1.3 Streptococcal Superantigens	p.7
1.1.4 Evolutionary Origin of Clone M1T1 GAS serotype from its parental M1 serotype	p.13
1.1.5 Disease model for invasive GAS serotype M1T1	p.16
1.2 Bacterial membrane vesicles	p.20
1.2.1 Background and History	p.20
1.2.2 What are Membrane Vesicles?	p.21
1.2.3 Regulation of Vesicles Biogenesis	p.22
1.2.4 Functions of MVs	p.24
1.2.5 MVs in Gram positive Bacteria	p.27
2. Study aim	p.30
3. Materials and Methods	p.31
3.1 Bacterial strain and growth conditions	p.31
3.2 Dna extraction	p.31
3.3 Molecular gene identification	p.31
3.4 Rna extraction	p.32
3.5 RT and q-RT-PCR	p.33
3.6 MVs isolation protocol	p.34
3.7 Purification of MVs	p.35
3.8 Scanning Electron Microscopy (SEM) analysis	p.37
3.9 Transmission Electron Microscopy (TEM) analysis	p.37

3.10 Dynamic Light Scattering (DLS)	p.37
4. Results	p.38
4.1 Molecular identification of <i>emm</i> -typing and MLST determination	p.38
4.2 Determination of antibiotic resistance profiles and virulence gene content	p.39
4.3 Gene expression study of some virulence toxins in different growth phases by Real-Time PCR	p.40
4.4 Secretion of MVs from Gram positive bacteria, <i>S. pyogenes</i>	p.45
5. Discussion	p.47
6. References	p.52

1. Introduction

The genus *Streptococcus* [Rosenbach, 1844] consists of catalase-negative, Gram-positive cocci which are arranged in pairs and chains and are usually facultatively anaerobic. *Streptococci* are a diverse collection of species inhabiting many body sites and they are both commensals and pathogens. In particular, nonpathogenic streptococci, are the most abundant bacterial species at the oropharyngeal level, and they have been found to exert an important role in the protection against pathogenic agents causing inflammation and infections [Tagg JR *et al.*, 2003]. Much attention has recently been devoted to the analysis of the oral microbiota to develop bacteriotherapy focused on prevention and/or treatment of upper respiratory tract infections. In this regard, a key species is *Streptococcus salivarius*, a lactic acid bacterium that is mainly encountered in the mouths of human beings. It is the first commensal bacterium that appears in the oral cavity of newborns where it colonizes the upper respiratory tract [Aas JA *et al.*, 2005] and persists there as a predominant member of the native microbiota throughout the life of its human and sole natural host [Favier CF *et al.*, 2002]. Many LAB (Lactic Acid Bacteria) strains, including *S.salivarius*, are prolific producers of bacteriocins, which are an abundant and diverse group of ribosomally synthesized antimicrobial peptides produced by bacteria that kill or inhibit species closely related to the producer bacterium. Furthermore, according to several studies, large populations of *S.salivarius* efficiently adhere to oral epithelial cells, especially the papillary surface of the tongue that is a strategic location to carry out a population surveillance within the oral microbiota [Tagg JR *et al.*, 1983; Wescombe PA *et al.*, 2010]. The presence of an adhesion system such as pili, fibrils, saliva-binding proteins and host-cell-binding

proteins, together with its high competition rate, helps this species to stay in the human mouth [Nobbs AH *et al.*, 2009].

In our laboratory, during my PhD studies, we characterized one strain, *S.salivarius* 24SMBc, isolated from one healthy child that showed excellent inhibitory activity against *S.pneumoniae* and *S.pyogenes* and a potent capacity of adhesion to HEp-2 cells. The main aim of this study was to evaluate the clinical evidence of a probiotic application of *S.salivarius* 24SMBc for the prevention or reduction of recurrent medium otite (OM) children [Santagati M *et al.*, 2014]. Therefore, this strain was included in a randomized, placebo-controlled, double-blind paediatric trial that involved 100 otitis prone children. This preliminary study showed a reduction of OM episodes in children who received the intranasal administration of this probiotic with respect to children treated with placebo [Santagati M *et al.*, 2014].

The study of *S.salivarius* 24SMBc ended with the production and marketing of a new medical device, the Rinogermina nasal spray, in collaboration with D.M.G s.r.l Italy. *Streptococci*, as mentioned above, include both nonpathogenic and pathogenic bacteria. In particular, *Streptococcus pyogenes* (group A streptococci, GAS) is an exclusive human bacterial pathogen. The virulence potential of this species is tremendous. Interactions with humans range from asymptomatic carriage over mild and superficial infections of skin and mucosal membranes up to systemic purulent toxic-invasive disease manifestations [Fiedler T *et al.*, 2015]. Simultaneously with the study of *S.salivarius* 24SMBc, my PhD project focalized on global regulation of virulence expression genes of three hypervirulent strains of *Streptococcus pyogenes* [Santagati M *et al.*, 2014] and their eventual production of membrane vesicles like new delivery system of virulence-associated components.

1.1 Streptococcus pyogenes

Group A streptococcus (GAS), or *Streptococcus pyogenes*, is a Gram-positive coccus and is an important human pathogen. GAS is usually present in the respiratory tract in 5 to 15% of individuals without signs of disease. As part of our flora, if defenses are compromised, *S.pyogenes* can generate a variety of suppurative infections. It is the most common cause of bacterial pharyngitis and is the cause of scarlet fever and impetigo. In the past, GAS strains were a common cause of puerperal sepsis or childbed fever. Today, group A streptococcus is responsible for streptococcal toxic shock syndrome and, recently it has gained notoriety as the “flesh-eating” bacterium which invades skin and soft tissues [Cunningham *et al.*, 2000]. It is also responsible for a diverse range of clinical manifestation, such as bacteremia, cellulitis, meningitis, pneumonia and necrotizing fasciitis [Lamagni *et al.*, 2008]. GAS causes an estimated 700 million cases of mild, non invasive infections each year, of which 650,000 progress to severe invasive diseases with 25% mortality [Carapetis J.R *et al.*, 2005]. Epidemiologic studies, in 2008, showed that the resurgence of severe invasive GAS infections represented a global spread, ushering in a new pandemic, similar to that reported in the earlier part of the 20th century [Aziz *et al.*, 2008].

1.1.1 Classification of GAS

Streptococci are classified on the basis of hemolysis, colony morphology and serologic specificity. They are divided into three groups by the type of hemolysis on blood agar:

- β -hemolytic (clear, complete lysis of red cells)
- α -hemolytic (incomplete, green hemolysis)
- γ hemolytic (no hemolysis).

GAS belongs to the beta-hemolytic streptococci family and it was defined in 1933 by Rebecca Lancefield as Group A Streptococcus on the basis of its specific cell wall polysaccharides (group A, B, C, F and G) or lipoteichoic acids (group D) [Lancefield R.C, 1933]. The Lancefield classification scheme of serologic typing distinguished the beta-hemolytic streptococci based on their group A carbohydrate, composed of N-acetylglucosamine linked to a rhamnose polymer backbone. A serological differentiation based on the most abundant exposed surface antigen, the M protein, is also extensively used in infection diagnosis and, over the years, the number of serotypes has progressively increased up to 150. Streptococci were also serologically separated into M protein serotypes based on a surface protein. Serotype M1 is among the most frequent serotypes from streptococcal pharyngitis and invasive diseases and the resurgence of severe invasive GAS infections is now correlated with single clone M1T1 GAS serotype [Musser JM *et al.*, 2007]. The M1T1 strains contain the bacteriophage-encoded virulence factors extracellular streptodornase D (Sda1) and exotoxin type A (SpeA). The acquisition of prophages encoding Sda1, SpeA and the recombination of a 36kb chromosomal region encoding an extracellular toxin NAD-glycohydrolase (NADase) and streptolysin O (SLO), were a crucial factor in dissemination, potential virulence and emergence of a very abundant clone serotype M1T1 GAS that are different from M1 GAS [Musser JM *et al.*, 2005] (**Fig.1.**)





Fig.1. Paul Sumbly *et al.* J Infect Dis. 2005

1.1.2 GAS Surface

Many GAS virulence factors are present on the bacterial cell surface, and of particular interest are those involved in colonization and evasion of the host immune responses. Invasive GAS disease requires successful colonization of skin or oropharynx. Initial weak interaction with mucosa, mediated by pili or lipoteichoic acid, is followed by a stronger binding lectine-carbohydrate and protein-protein interactions that confer tissue specificity. Group A Streptococcus has a highly complex and diverse cell surface, rich in antigenic components such as the polysaccharide capsule (C-substance), the cell wall peptidoglycan and many surface proteins including the M protein, fimbrial and fibronectin-binding proteins [Walker MJ *et al.*, 2011].



M Protein

The streptococcal M protein is now probably one of the best-defined molecules of the known bacterial virulence determinants. The M protein is a major surface protein and virulence factor of group A streptococci, with more than 150 distinct serotypes identified. The amino-terminal region extends from the surface of the streptococcal wall, while the carboxy-terminal region is within the membrane. The serotype specificity of GAS is determined by N-terminal region, called the A repeat region, that is highly variable among M serotypes. The B repeat region, the mid-region, varies from serotype to serotype and the carboxy-terminal or C repeat region contains a conserved sequence shared among all of the serotypes [Fischetti *et al.*, 1989]. The M proteins are able to bind serum fibrinogen allowing the bacteria to resist phagocytosis and contain those particular epitopes that mimic human tissues, some of these are the cause of rheumatic fever, leading to an autoimmune carditis. Furthermore, M protein increases bacterial survival in neutrophils, so this protein is essential for full virulence during GAS infection. Epidemiological studies have shown a clear correlation between M-type and type of infection caused, partitioning the group of *S.pyogenes* into two classes:

- Class I (M-types: 1, 3, 5, 6, 14, 18, 19, 24) are found associated with throat infection and rheumatic fever.
- Class II (M-types: 49, 57, 59, 60, 61) produce serum opacity factor (SOF) and are associated with pyoderma and acute glomerulonephritis. [Cunningham *et al.*, 2000].

The Streptococcal Capsule

The group A streptococcal capsule is composed of a linear polymer of hyaluronic acid containing repeating units of glucuronic acid and *N*-acetylglucosamine that is produced by enzymes encoded in the highly conserved *has ABC* hyaluronan synthase operon [PH Weigel. J *et al.*, 1995]. The *hasA* gene encodes hyaluronate synthase; *hasB* encodes UDP-glucose dehydrogenase [Crater DL *et al.*, 1993]; and *hasC* encodes UDP-glucose pyrophosphorylase. The hyaluronic acid capsule is required for resistance to phagocytosis [Wessels MR *et al.*, 1994] and may be an important adherence factor during host colonization because it is able to bind CD44 on epithelial cells [Wessels MR *et al.*, 1998]. Glucuronic acid and *N*-acetylglucosamine, nearly identical to the polysaccharides that are in the human host, encourage GAS evasion of the host immune response. Streptococcal isolates have different amounts of hyaluronic acid capsule that could be related to the *has* operon promoter. In the well-encapsulated strain, the promoter is more active than in a poorly encapsulated strain [Wessels MR *et al.*, 1998]. Furthermore, Levin and Wessels demonstrated that capsule production and virulence is highly influenced by a negative regulator (CsrR) that is part of a two-component regulatory system [Levin J *et al.*, 1998]. More recent work provides definitive evidence that the capsule is a major virulence determinant involved in resistance to phagocytosis in conjunction with the streptococcal M protein.

1.1.3 Streptococcal Superantigens

Streptococcus pyogenes has acquired many virulence determinants that allow it to survive within the host and they are involved in the pathogenesis of toxic shock, necrotizing fasciitis, and invasion of soft tissue and skin. The superantigens (Sags)

are the extracellular pyrogenic exotoxins A, B, C (SpeA, SpeB, SpeC) and newly discovered exotoxins such as exotoxin F (SpeF) and streptococcal superantigen (SSA) [Holm SE *et al.*, 1994]. All of these toxins act as superantigens that interact with the major histocompatibility complex (MHC) class II molecule via high zinc binding and the activation liberates large amounts of interleukins and other inflammatory cytokines such as gamma interferon and tumor necrosis factor. Furthermore, the superantigens are able to bind the beta chain (V β) of the T-cell subset without any processing by antigen-presenting cells. The pyrogenic exotoxin *speA* and *spec* are encoded by bacteriophages [Cunningham *et al.*, 2000], while *speB* is chromosomal and it is a cysteine proteinase that degrades vitronectin, fibronectin, and IL-1 precursor.

Streptolysin O

SLO is part of a family of cholesterol-binding cytotoxins produced by many pathogenic Gram-positive bacteria including *Streptococcus pneumoniae* (pneumolysin), *Listeria monocytogenes* (listeriolysin O) and *Bacillus anthracis* (anthrolysin) [Rest RF *et al.*, 2003]. SLO is a 69 kDa protein that oligomerizes to form large pores in the host cell membrane [Tweten RK *et al.*, 2000], and has several functions in GAS pathogenesis, including the induction of apoptosis in epithelial cells, neutrophils and macrophages [Timmer AM *et al.*, 2009]. SLO, also, prevent direct uptake of GAS into lysosomes and enhances GAS survival in the human host by interfering with both bacterial uptake and intracellular killing of GAS by pharyngeal epithelial cells.

Streptococcal inhibitor of complement, SIC

The *sic* gene, which encodes the Streptococcal inhibitor of complement-mediated lysis (SIC), is a highly polymorphic extracellular protein and putative virulence factor secreted only by M1 and M57 GAS strains. SIC is a secreted 31 kDa protein that is located in the Mga virulence regulon [Akesson P *et al.*, 1996]. Sic was shown to bind C5b67 of the membrane attack complex (MAC), thus impairing terminal complement function. In particular, SIC promotes GAS MIT1 survival and enhance the progression of invasive infection.

C5a peptidase

The endopeptidase C5a is a 130 kDa proteolytic enzyme localized on the surface of GAS strains. The C5a peptidase is encoded by a gene that is regulated by *mga* in concert with M protein [LaPenta, D *et al.*, 1994]. Peptidase cleaves the complement-derived chemotaxin C5a at its PMN-binding site [Cleary P *et al.*, 1992] and this event inhibits the recruitment of phagocytic cells to the site of infection [Cleary PP *et al.*, 1996]. The identity of the amino acid sequence of the enzyme is greater than 95% among class I and class II M protein serotypes of group A and B streptococci. Consequently, the surface of GAS presents a double barrier to the complement defenses of the host: first, the M protein, discussed above, and second, the streptococcal C5a peptidase inactivates C5a and chemotaxis.

Streptodornase D

One important distinguishing feature of global dissemination of the MIT1 GAS clone, compared to less pathogenic GAS strains, is the acquisition of a prophage (Φ MIT1Z) encoding a potent secreted DNase, Sda1 [Aziz RK *et al.*, 2004]. This gene has been shown to promote MIT1 GAS virulence via

degradation of NETs. NETs are composed of DNA, granule protease, antimicrobial peptides and histones that are secreted by host neutrophils to capture and eliminate bacteria at the site of infection [Cole JN *et al.*, 2011; Buchanan JT *et al.*, 2006; Walker MJ *et al.*, 2007]. The presence of Φ M1T1Z and a second prophage that encodes the superantigens SpeA, distinguishes the GAS serotype M1T1 from its closely related M1 type.

Streptococcal exotoxin B, SpeB

SpeB, a cysteine proteinase, is the most secreted protein from *S.pyogenes*. The streptococcal cysteine proteinase is one of the best studied and the earliest identified secreted proteins from *S. pyogenes*. Much is known about its structure, function, processing, substrate specificity and regulation [Ashbaugh *et al.*, 1998; Ashbaugh and Wessels, 2001]. Despite the large amount of literature on SpeB functions, the role of SpeB in GAS infections is still unknown, but recent evidence has conclusively demonstrated that SpeB is critical for the pathogenesis of severe invasive disease caused by GAS. *speB* is a chromosomal gene and is highly conserved and found in > 99% of GAS isolates, although there is a significant variation in expression levels among strains [Bohach *et al.* 1988; Ferretti J *et al.*, 1991]. The gene encodes the 398 amino acid SpeBz (40 kDa) and undergoes conversion to mature 28-kDa SpeBm form by autocatalytic truncation [Liu and Elliott 1965b; Doran *et al.*, 1999]. This enzyme is able to degrade the extracellular matrix, cytokines, chemokines, complement components, immunoglobulins, serum protease inhibitors, and also cleaves and inactivates many surface-associated and extracellular GAS virulence determinants, including M1 protein, [Ringdahl U *et al.*, 2000], different superantigens, [Aziz RK *et al.*, 2004; Kansal RG *et al.*, 2003],

streptokinase [Sun H *et al.*, 2005], Sda1 [Aziz RK *et al.*, 2004], and SIC [Pence M A *et al.*, 2010]. Furthermore, SpeBm can cleave the cell wall-anchored C5a peptidase from the bacterial surface and this causes the inhibition of recruitment of neutrophils to the site of infection [Wexler and Cleary, 1985; Berge and Björck, 1995]. As a consequence, the bacterial properties are altered, which is important for the transition from localized to systemic *S.pyogenes* infection [Cole *et al.*, 2006]. Regulation of *speB* expression in GAS is extremely complicated. Maximal expression occurs from late logarithmic to stationary phase in response to environmental factors, pH and NaCl concentration. Although there are many papers on *speB* expression, the precise regulatory mechanisms that occur *in vivo* remain unclear. [Musser *et al.*, 2011]. During the different stages of an infection or response to external stresses from the environment, GAS strains are able to control transcriptional regulation of genes and protein secretion through signal peptidases. The cumulative contribution of the secreted cysteine protease SpeB to the pathogenesis of invasive GAS infection is at present unclear, and studies in various GAS serotypes and animal models have produced varying results. The Streptococcal exotoxin B is involved in bacterial phenotype shift in different ways. For example, in some *S.pyogenes* strains, deletion of the *speB* gene leads to a down regulation of gene encoding for the hyaluronic acid capsule, but the underlying molecular mechanism is not well understood [Woischnik *et al.*, 2000]. Some studies have shown that a high production of SpeB is associated with STSS, whereas others show that low SpeB production is associated with severe infection [Talkington *et al.*, 1993; Kansal *et al.*, 2000]. Musser's group demonstrated, in different papers that, using *speB* mutants in animal models, they all showed that SpeB contributes to tissue damage and bacterial dissemination

[Lukomski *et al.*, 1997, 1998, 1999]. Later, Kotb's group showed that SpeB is downregulated in invasive M1T1 isolates during infection in mice [Kazmi *et al.*, 2001]. Recently, Aziz's group, in 2004, demonstrated that GAS M1T1 WT, SpeB-positive bacteria undergo a phase-shift to the speB-negative phenotype after infection in mice [Aziz RK *et al.*, 2004]. This phase switch was observed to be the result of mutations in the two-component regulatory system covR/S [Walker MJ *et al.*, 2007]. CovR/S is a global regulator, also called CsrR/S, a two component signal (TCS) transduction system that has been studied extensively because of its critical role in virulence. Normally, covR/S represses expression of about 15% of GAS genes including many involved in virulence [Federle *et al.*, 1999]. Some studies have revealed a correlation between an invasive phenotype and the up-regulation of some virulent genes, coding proteins such as streptodornase, streptokinase, streptolysin O, streptococcal inhibitor of the complement and the hyaluronic acid capsule synthesis operon [Sumbly P *et al.*, 2006]. At the same time, a mutation in the covR/S operon, decreases the expression of speB and consequently prevents the degradation of streptokinase and the M1 protein. The presence of these proteins promotes invasive infection and bacterial dissemination. [Cole *et al.*, 2006]. Furthermore, studies of M1T1 clinical isolates from invasive disease cases, found an inverse relationship between SpeB expression and clinical severity. In particular, SpeB levels were higher in GAS M1T1 serotype isolates from non-severe invasive infections than in isolates from severe cases, such as STSS and necrotizing fasciitis. [Kansal *et al.*, 2000]. In conclusion, the precise function of streptococcal exotoxin B is extremely complex and for this reason is still unknown, because different studies have produced contradictory results [Svensson MD *et al.*, 2000; Ashbaugh and Wessels, 2001;

Lukomski *et al.*, 1997, 1998, 1999]. Together the data suggest that the effects of SpeB during the interaction between host-bacteria *in vivo* will depend on the balance between the actions of several regulatory systems that control SpeB synthesis, post-translational modification, and enzymatic activity [Kansal *et al.*, 2000] (**Fig.2.**).




Fig.2. Model explaining mutation of *Streptococcus pyogenes* regulatory locus during invasive infection. Claire Turner & Shiranee Sriskandan *Nature Medicine* (2007)

1.1.4 Evolutionary Origin of Clone MIT1 GAS serotype from its parental M1 Serotype

Genome sequencing, DNA-DNA microarray, PCR profiling, single-nucleotide polymorphism analysis, and several other genetic analysis techniques have highlighted the origin of a new clone, MIT1, genetically distinct from the serotype M1 strains, responsible for most recent human infections. Usually, bacteria can evolve slowly through the accumulation of point mutations or more quickly by horizontal gene transfer events, such as conjugation, transformation and prophage transduction [Ochman H *et al.*, 2000]. Nevertheless, the exact molecular mechanisms that lead to the onset of unusually virulent pathogens are still unclear. Recently,

Musser's group have demonstrated the evolutionary origin of a new clone serotype derived from its parental M1 GAS serotype. In the past, serotype M1 GAS was the pathogen responsible for most invasive diseases, such as STSS, NF, and septicemia, but during the mid-1980s, the frequency of invasive infection caused by serotype M1 GAS suddenly increased [Musser JM *et al.*, 1998]. Musser's studies have shown that there are two main events that contribute to the evolutionary origin of the hypervirulent clone M1 GAS:

- acquisition of two prophage genes: streptococcal pyrogenic exotoxin A (*SpeA*) and streptodornase D (*Sda1*)
- the recombination of a 36-kb chromosomal region from M12 serotype encoding NADase (extracellular toxin NAD⁺ - glycohydrolase) and SLO (streptolysin O)

MGAS5005 is genetically representative of new serotype M1T1 strains causing contemporary infections. This clone evolved from a less virulent ancestor, SF370, through a series of recombination events. MGAS5005 was isolated for the first time in 1996 from the cerebrospinal fluid of an infected patient in Ontario, Canada, and has been used in many studies of GAS pathogenesis [Virtaneva K *et al.*, 2003; Voyich JM *et al.*, 2001; Sumby P *et al.*, 2005], while SF370 was isolated in 1985 from the infected wound of a patient [Ferretti JJ *et al.*, 2001; Smoot JC *et al.*, 2002; Beres SB *et al.*, 2002; Stevens DL *et al.*, 2000]. Consistent with the data from the DNA-DNA microarray analysis, the genomes of strains MGAS5005 and SF370 showed a strong similarity. **(Fig.3)**




Fig.3. Atlas comparing the chromosomes of strains SF370 and MGAS5005. Paul Sumby *et al.* J Infect Dis. 2005.

Even if MGAS5005 has three genes that encode putative secreted DNases. Two of these genes are associated with prophages (*spd3* carried by prophage $\Phi 5005.2$ and *sdaD2* by prophage $\Phi 5005.3$), and one is chromosomally encoded (*spd*). DNA-DNA microarray analysis among 30 serotype M1 isolates from 6 countries [Musser *et al.*, 2005] (**Fig.4**) found a match of core genomes to 93% of the ORFs present in the genome of the reference serotype SF370 strain. [Ferretti JJ *et al.*, 2001]. The prophage regions $\Phi 5005.1$ and $\Phi 5005.3$ of MGAS5005 strain were organized in ORFs similar to the sequenced genomes of M3 and M18 serotypes [Smoot JC *et al.*, 2002; Beres SB *et al.*, 2002]. Furthermore, the genomes of MGAS5005 and SF370 differ for small insertions and deletions, and many SNPs. Musser *et al.* showed that the majority of SNPs between these two strains were localized in a 36-kb region that extends from *purA* to *nadC*, which is virtual identical to the chromosomal region present in the M12 genome serotype. Although it seems clear that lateral gene transfer was involved in the 36-kb region from M12 serotype, there are no experiments which prove the molecular mechanism [Musser *et al.*, 2005] (**Fig.5**).




Fig.4. Schematic comparing the gene content of 29 serotype M1 group A Streptococcus (GAS) isolates with that of reference strain SF370. Paul Sumby et al., J Infect Dis. 2005




Fig.5. Open reading frame (ORF) map of a 51-kb region in the genomes of strains MGAS9429 (serotype M12), MGAS5005 (serotype M1), and SF370 (serotype M1). Paul Sumby et al., J Infect Dis. 2005

1.1.5 Disease model for invasive GAS serotype M1T1

In Group A Streptococci thirteen TCSs have been identified, but the best characterized is the CovRS system (also known as CsrRS). This Two Component regulatory System is required for survival of bacteria under

environmental stress conditions, such as low pH, iron starvation [Dalton TL *et al.*, 2004; Froehlich B *et al.*, 2009] high concentrations of NaCl, elevated temperature, and response to antibiotic stress [Sawai J *et al.*, 2007]. CovS is a sensor kinase localized on the membrane surface that is able to change the state of phosphorylation of the regulatory response, CovR [Dalton TL *et al.*, 2004], which is essential for growth under stress conditions [Froehlich B *et al.*, 2009; Sway J *et al.*, 2007]. CovRS is a negative regulatory TCS that directly or indirectly influences expression of 10% to 15% of GAS genes, including several virulence factors [Levin J *et al.*, 1998; Federle *et al.*, 1999; Graham MR *et al.*, 2002 and 2005; Gryllos I *et al.*, 2003; Engleberg NC, *et al.* 2001]. Mutations in the genes encoding the CovRS system in GAS serotype M1T1 affect the expression of virulence factors that are important determinants of the pathogenesis of these invasive bacterial strains. Phosphorylated CovR seems to negatively regulate many genes, including *speB*, *HasA*, *ska*, *Sda1* and *sagA* [Heath A *et al.*, 1999; Engleberg NC *et al.*, 2001-2004], but the mechanism by which CovR function is not yet fully understood. Sumby *et al.*, using an Affymetrix expression microarray, analyzed nine strains of serotype M1, including six from patients with pharyngitis and three from invasive disease episodes. This study showed a completely different transcriptome cluster based on the analysis of the microarray data (**Fig. 6A**), which were designated pharyngeal transcriptome profile (PTP) for the six pharyngitis isolated, and invasive transcriptome profile (ITP) for the three invasive isolated [Sumby *et al.*, 2006]. All PTP isolates had wild-type *covR/S* genes, while all ITP isolates had either a mutated *covR* or *covS* gene. The two transcriptomes differ by

approximately 10%, and the genes with differences include multiple known and putative virulence-associated genes. Furthermore, GAS isolates with ITP profile were recovered from mice that were subcutaneously with PTP GAS, proving a bacteria shift phenotype *in vivo*-selected [Kazmi *et al.*, 2001]. The increased virulence of ITP GAS in the bacteremia model was linked to up-regulation of many factors that inhibit PMN function, including capsule, Sic, C5a peptidase, and other important virulence factors, whereas the level of *speB* mRNA was downregulated. SpeB, as we have already described above, degrades fibronectin, vitronectin, and other host molecules [Aziz RK *et al.*, 2004; Rasmussen M *et al.*, 2002; Kapur V *et al.*, 1993], and also cleaves some bacterial proteins. Thus, decreased SpeB production may play a key role in the increased virulence of ITP GAS by preserving GAS virulence factors [Aziz RK *et al.*, 2004; Raeder R *et al.*, 1998; Wei L *et al.*, 2005]. However, the *in vivo* consequences of this *in vitro* observation are unclear. Taken together, all these data hypothesize that CovS regulates CovR to enhance the repression of one subset of genes *speA*, *hasA* and *ska*, while at the same time reducing the repression of a second subset of genes *speB*, *grab* and *spd3* (encoding a streptodornase) (**Fig. 6B**), [Trevino J *et al.*, 2009]. For this reason, it has been proposed that phosphorylated CovR represses promoters of the first gene subset, whereas non-phosphorylated CovR represses the second gene subset [Trevino J *et al.*, 2009; Churchward G *et al.*, 2007]. Kensal *et al.* reported a similar phenomenon that MIT1 AP (hypervirulent animal-passaged, with SpeB⁻/ SpeA⁺/ Sda^{high} phenotype), which are hardly detected in a WT population (SpeB⁺/ SpeA⁻/ Sda^{low} phenotype), become the bacterial majority community *in*

vivo, maybe because they have a survival advantage due to over expression of certain virulence genes. In conclusion, the identification of covRS mutations in highly virulent GAS serotypes isolated from human patients with severe disease suggests a key role for survival and persistence in distinct environmental niches [Aziz RK *et al.*, 2010], in contrast to the wild-type phenotype, which is better adapted for the initial stages of the infection. Although it is still unclear how this highly complex system works, it is clear that there is a link between Δ CovRS and the hypervirulent strain. Probably, in the future, we will need detailed structure-function studies and more analyses of the ways that different stimuli can affect CovS and consequently CovR, to better understand the exact molecular mechanism.




Fig.6A-B. Differential Gene Expression of ITP and PTP GAS. Sumby P. Plos, 2005.

1.2 Bacterial Membrane Vesicles

1.2.1 Background and history

Bacteria have evolved over the millennia to survive in a wide variety of environments. Regardless of living location, the microbes have had to evolve different tools to grow in environments subject to change. One such tool that facilitates microbe-microbe, microbe-host and microbe-environment interactions is the production of membrane vesicles (MVs). The first discovery of MVs was made over five decades ago, and it is now clear that the production of OM vesicles has been observed for a wide variety of Gram negative bacteria in all stages of growth as well as in a variety of growth conditions, such as infected tissues, with *Pseudomonas aeruginosa* and *Escherichia coli* because they are the most studied bacteria model. Vesicles were discovered first by T.J. Beveridge and colleagues, who is still considered the undisputed pioneer of the biological roles of MVs and mechanism of MV formation. The content, composition and purpose of these structures were unknown. For most of the time, the study of MV formation by prokaryotes has focused only on Gram negative bacteria. Recently, attention has turned to determining if MV production is also possible in Gram positive bacteria. Now we know that the production of spherical membranous vesicles is shared among all three branches of the tree of life: eukaryotes, Gram negative and Gram positive bacteria [Lee EY *et al.*, 2009; McBroom AJ *et al.*, 2005; Rivera J *et al.*, 2010], archaea [Ellen AF *et al.*, 2010], fungi [Oliveira DL *et al.*, 2010], and parasites [Silverman JM *et al.*, 2008-2010]. The release of MVs plays an integral role in cell physiology and the pathogenesis of infection. As the OMVs are known to

induce the immune system, they have been recognized as promising agents to be used as vaccines. Recently, one successful example is a vaccine for meningitidis caused by *Neisseria meningitidis* [Findlow *et al.*, 2006; Boutriau *et al.*, 2007; Williams *et al.*, 2007]. Besides direct medical applications, the study of OMVs is also an opportunity to better understand the physiology of bacteria.

1.2.2 What are MV Vesicles?

Bacterial membrane vesicles are closed spheroid particles produced by both Gram positive and Gram negative bacteria. The outer membrane (OM) vesicles of Gram-negative bacteria have a heterogeneous size from 10 to 300 nm in diameter, while the MVs secreted by Gram-positive bacteria have a smaller diameter between 20 to 150 nm [Dorward and Garon, 1990; Lee *et al.*, 2009; Rivera *et al.*, 2010]. In general, MV vesicles reflect the composition of the outermost portion of the membrane from which they derive, thus the OM vesicles derived from Gram-negative bacteria containing LPS, glycerophospholipids, and OM proteins as well as enclosed periplasmic components [Gankema H *et al.*, 1980; Hoekstra D *et al.*, 1976; Horstman AL *et al.*, 2000; Kadurugamuwa JL *et al.*, 1995; McBroom AJ *et al.*, 2005] (**Fig.7**). Just as there are differences in the envelope structure among Gram positive and Gram negative bacteria, MVs are completely different in composition in these two types of microorganism. Gram positive MVs originate from the cytoplasmic membrane and proteomic studies show they are composed mostly of cytosolic protein, cytoplasmic membrane-associated protein, as well as some secreted protein [Gurung *et al.*, 2011].





Fig.7. Model of vesicle biogenesis. (LPS) Lipopolysaccharide; (Pp) periplasm; (OM) outer membrane; (PG) peptidoglycan; (IM) inner membrane; (Cyt) cytosol. Meta J. Kuehn, 2005. Genes & Development.

1.2.3 Regulation of vesicle Biogenesis

OMVs are secreted by bacteria both in liquid and on solid media, as well as *in vivo*.

The goal of many OMV studies has been to understand how OMVs are formed and how this process is regulated, but is still poorly understood. Initially it was thought that the formation of OMVs was a physical process associated with the turnover of cell OM [Haurat *et al.*, 2011]. Although this idea is still held by some, recent discoveries show that there is likely to be an elaborate mechanism behind the biogenesis of OMVs. There are several reports indicating that vesicles form as a response to membrane stress [McBroom AJ *et al.*, 2007], however, the fact that membrane vesicles are released even when the cells grow without external stress makes it difficult to think that MV biogenesis is exclusively a stress response. For Gram-negative OMVs, several models of biogenesis have been hypothesized based on architectural features of the envelope and vesiculation mutants [Beveridge *et al.*, 1999; Deatherage *et al.*, 2009; Kulp and Kuehn, 2010]. Three mechanisms have been

proposed for vesicles biogenesis: (i) the accumulation of misfolded protein in the periplasm, may result in a mechanic force that literally pushes out the outer membrane and eventually leads to the release of OMVs; (ii) some external agents that could intercalate into the outer membrane and as a consequence membrane packaging is disturbed; (iii) some small molecules that normally are secreted through the cell envelope could change the regulation of genes, causing an increment or decrement of levels of OMVs (**Fig.8**).



In contrast to OMVs, the mechanisms and regulation of MVs of Gram positive bacteria have not yet been completely understood. OMV biogenesis is often considered to be stress regulated, in fact, OMV levels are modulated by altering levels of envelope proteins, temperature, and quorum sensing signals, and antibiotic treatment has been demonstrated to influence several aspects of vesiculation. For

example, gentamicin and mitomycin affect the secretion and composition of OMVs in Gram-negative bacteria. The level of Shiga toxin-associated OM vesicle production by *Shigella dysenteriae* increased with mitomycin [Dutta S *et al.*, 2004]. Release of MVs by *Pseudomonas aeruginosa* increased approximately threefold after exposure of the organism to four times the MIC of gentamicin [Kadurugamuwa JL *et al.*, 1995]. The antibiotic ciprofloxacin interacts with DNA synthesis and leads to an SOS response, which was found to be involved in increasing OMV levels. Vesiculation was found in both nonpathogenic and pathogenic species, under a range of growth conditions, including in liquid broth and on agar plates in the laboratory [Deatherage BL *et al.*, 2009; Silverman JM *et al.*, 2008], in biofilms [Schooling SR *et al.*, 2006], upon infection with bacteriophages [Loeb MR *et al.*, 1974], and in pathogenic organisms growing within an animal host [Feldmesser M *et al.*, 2001; Fiocca R *et al.*, 1999, Marsollier L *et al.*, 2007, Necchi V *et al.*, 2007]. In general, pathogenic microbes produce more OMVs than nonpathogenic ones, such as enterotoxigenic *E.coli* (ETEC) that produces about 10-fold more vesicles than nonpathogenic *E.coli* [Horstaman and Kuehn, 2002].

1.2.4 Function of MVs

Several studies have shown many different functions for bacterial membrane vesicles. The main idea is that vesicles are necessary for the survival of the bacteria that produce them. MV release is essential for promoting interactions between microbial cells and between eukaryotic host cells and microbes, including communication, release of antigens, and secretion of virulence factors (**Fig. 9**).




Fig. 9. Biological impact of MV release. Brooke L. Deatherage, and Brad T. Cookson *Infect. Immun.* 2012.

OMVs produced from one bacterium can kill other competing microbes in the same niche, and in this way bacteria destroy coinfectors to prevent competition for limited nutrients. The predatory nature of MVs was described in *P.aeruginosa* that has the ability to kill other Gram negative as well as Gram positive bacteria [Li et al., 2008]. In a recent study, Vasilyeva *et al* found that *Lysobacter* spp. XL1 secreted bacteriolytic enzymes in OMVs [Vasilyeva NV *et al.*, 2008]. This activity of OMVs shows that they might be capable of distinguishing between self and non-self cells in a mixed community, thus vesiculating bacteria may have a survival advantage in mixed-population infections thanks to their capacity to eliminate competing bacterial strains. Furthermore, OMVs play a role in biofilm formation and maintenance. Biofilm formation is characterized by the expression of genes responsible for


exopolysaccharide production and co-aggregation of cells. Analyses of OM vesicle components have demonstrated that vesicles contain a wide variety of virulence factors. These virulence factors include protein adhesins, toxins, enzymes and antigens such as lipopolysaccharide (LPS). Kadurugamuwa and Beveridge showed that MVs liberated from *Pseudomonas aeruginosa* contain many virulence factors and are important in disease pathogenesis. Factors packaged into *P.aeruginosa* MVs include phospholipase C, proteases, alkaline phosphatases, and hemolysins. Although to date the real benefit to transport toxin and virulence factors by MVs is still unclear, Beveridge proposed two advantages: (i) the virulence toxin inside the MVs could be more concentrated and more focused to target cells; (ii) virulence factors transported by MVs may protect from degradation and recognition by host factors or microorganism. In addition, vesicles can facilitate the horizontal transfer between bacteria and this contributes to genetic diversity and bacterial survival. For example, *M.catarrhalis* which carry β -lactamase within MVs, is able to transfer resistance-antibiotic genes to *S.pneumoniae* and *H.influenzae* and to promote survival of these bacteria in the presence of antibiotic amoxicillin [Shaar *et al.*, 2001b]. Recently, Fulsundar *et al.*, have shown that OMVs from *Acinetobacter baylyi* were found to transfer small DNA fragments to *E. coli* [Fulsundar *et al.*, 2014]. Vesicle surface factors can mediate adhesion with eukaryotes and, as a consequence, vesicle materials can be internalized. The presence of bacterial membrane vesicles during infection processes has been observed in many human samples and infected tissue. Several reports of clinical isolates of *H.pylori* show OMVs in contact with epithelial cells. [Fiocca *et al.*, 1999; Keenan *et al.*, 2000]. In

studies of *S.aureus* and *B.anthraxis*, MVs were found to be lethal to host cells [Gurung *et al.*,2011; Rivera *et al.*; 2010].

The mechanism of adherence and internalization is still the subject of many studies, however, OMV adherence has been studied in molecular detail for heat-labile enterotoxin (LT) of enterotoxigen *E.coli* [Horstman and Kuehn, 2002]. It is clear that vesicles contain compounds that are recognized by eukaryotic cells in the innate and acquired immune response pathways. Alaniz *et al.*, demonstrated that OMVs from *Salmonella enteric* serovar *Typhimurium* are potent stimulators of proinflammatory cytokine secretion. *Salmonella* OM vesicles determine the increased expression of tumor necrosis factor alpha and interleukin-12. The ability of bacterial membrane vesicles to trigger inflammatory response to pathogens has led to the development of immunogenic vaccines. Many studies have focused on investigating the potential of OMVs as vaccines for pathogens including *Neisseria meningitides*. A study carried out in Cuba showed that the OMV vaccine had a promising efficacy of 83-94% [Sierra GV *et al.*, 1991]. More recently, a vaccine containing three *N.meningitides* surface antigens was developed in order to provide broad protection and minimize the risk of escape through mutations. New bacterial and viral disease are emerging, and at the same time there is a decline in the efficacy of antibiotics. For this reason, the application of OMVs holds some promise in this context.

1.2.5 MVs in Gram positive bacteria

Despite the fact that the discovery of membrane vesicles in Gram-negative bacteria goes back at least 40 years, MVs have been overlooked in Gram-positive bacteria. This lapse might be attributed to the very different composition of the cell wall between these bacteria.



Recently, it has been demonstrated that MVs can be produced by Gram-positive bacteria, such as *S.aureus* and *B.anthraxis* [Lee *et al.*, 2009; Rivera J *et al.*, 2010]. Similarly, MVs shed from both strains are bilayer spherical vesicles, but the size is smaller than OMVs from Gram-negative bacteria. For the first time, Lee and colleagues showed that MVs from *S.aureus* contain many virulence factors and toxins, such as adhesins, proteolysin, coagulase and many other related enzymes that are implicated in infections of humans [Lee *et al.*, 2009]. A few years later, Gurung *et al.* demonstrated that *S.aureus* secretes membrane vesicles into the extracellular milieu during *in vivo* infection and the protein A, one of the toxins from *S.aureus*, can be efficiently delivered by intact MVs, whereas the protein A from lysed MVs is unable to enter the cytosol of the host cell [Gurung M *et al.*, 2011]. *Streptococcus pneumoniae* also produces membrane vesicles, although these vesicle are biologically and biochemically different from the plasma membrane from which they derive [Olaya-Abril A *et al.*, 2014]. In particular, MVs are more enriched in lipoproteins and transmembrane proteins than in the plasma membrane. Furthermore, MVs do not have lipoteichoic acid, a typical molecule on the surface of Gram-positive bacteria. Proteomic analysis showed that MVs have a different fatty acid

composition: short-chain saturated fatty acids, conferring much more fluidity than the plasma membrane, consist of large amount of long-chain fatty acids. This might be, at least in part, an explanation for the biogenesis of membrane vesicles from the very hard cell wall of Gram-positive bacteria [Mercier R *et al.*, 2012]. More recently, a large amount of lipoproteins organized in vesicles was isolated from *Streptococcus pyogenes* [Biagini *et al.*, 2015]. Proteomic analysis of the vesicles revealed that they were composed of phosphatidylglycerol and lipoproteins. Bacterial lipoproteins are possible vaccine candidates because they are a major class of cell-surface proteins that are sensed by Toll-like receptors. Although, MVs shed by this bacterium are composed of lipoproteins, those structures do not act in a pathogen-associated molecular pattern [Biagini *et al.*, 2015]. Taken together, these results seem to indicate that MVs serve as a transport system for virulence-associated components. During my PhD project, I tried to check, for the first time, if *Streptococcus pyogenes* can also be a producer of membrane vesicles and whether this could explain the hyper virulence of some *Streptococcus* strains due to the delivery of some toxins within MVs.

2. *Study Aim*

During my PhD at the Microbial Molecular Antibiotic Resistance (MMAR) laboratory my research line focused on molecular characterization and evaluation of genetic expression in different growth phases of three hyper virulent strains of *S.pyogenes*, isolated in different Italian hospitals, that were responsible for serious cases of acute necrotizing pneumonia that led to the rapid death of patients due to respiratory failure, sepsis and necrotizing hemorrhagic pneumonia [Santagati M, 2014]. Simultaneously to the molecular characterization of clinical isolates, we assessed a production of membrane vesicles (MVs) by *Streptococcus pyogenes* during growth, hypothesizing that these structures could vehicle some toxins to explain the hyper virulence of our sample used in this study.

In this study, three strains of *S.pyogenes* were included:

1. RM1, isolated in Umberto I Hospital, Rome
2. RMG1, isolated in Agostino Gemelli Hospital, Rome
3. CT1, isolated in Vittorio Emanuele Hospital, Catania

The phases of the trial plan were:

- I. Molecular identification of *emm*-typing and MLST determination
- II. Determination of the antibiotic resistance profile and virulence gene content by PCR and sequencing
- III. Gene expression study of some virulence toxins in different growth phases by Real-Time PCR
- IV. Isolation and analysis of membrane vesicles by TEM

3. Materials and Methods

3.1 Bacterial strain and growth condition. All GAS serotype M1T1 strains were previously isolated from different patients with an invasive GAS infection [Santagati M, 2014]. One clinical strain (CT1) was isolated from the emergency department (ED) of Vittorio Emanuele Hospital in Catania, Italy, in July 2012. RM1 was isolated from the ED of the University of Rome Medical Center. RMG1 came to the ED of the Catholic University Medical Center in Rome in February 2012. All of these strains were tested for susceptibility to antibiotics and for the presence of virulence genes by the PCR method [Santagati M, 2014].

We also used two representative GAS M1 serotypes, SF370 [Ferretti, J. 1991] and serotype M1 strain MGAS5005 were obtained from the American Type Culture Collection (ATTC No.BAA947) [Graham MR, 2002]. All of these strains were grown *in vitro* in Brain Heart Infusion broth with 0.2% yeast extract at 37°C with 5% CO₂.

3.2 DNA extraction. For each sample, all colonies grown on Columbia Agar Base, plus 5% horse blood were collected and washed with 1 ml of a solution of 0.9 % w/v NaCl. Then, microbial DNA was extracted and purified through a QIAcube Extractor using the QIAamp DNA Mini kit (Qiagen, Limburgo, NL). The DNA concentration (absorbance at 260 nm; A_{260}) and the purity (A_{260}/A_{280}) were calculated using a BioPhotometer D30 (Eppendorf, Hamburg, Germany).

3.3 Molecular gene identification. The molecular identification of strains, *emm*-type and virulence genes was performed by PCR assays. *emm* typing was performed by PCR using protocols and the database of the Centers for Disease Control and Prevention (Atlanta, GA, USA; www.cdc.gov/ncidod/biotech/strep/M-

[ProteinGene_typing.htm](#)). Strains were tested for multiple virulence genes (**Table 1**) by using the PCR assay [Santagati M, 2014].

Gene*	Primer name†	Primer sequence, 5'→3'	Amplicon size, bp
<i>slo</i>	MS442	GGTAACCTTGTTACTGCTAATGCTGA	400
	MS443	TAATGGAAATATCGACTGGTGTAGTG‡	400
<i>speA</i>	speA-fw	CTCAACAAGACCCCGATCCAAG	500
	speA-rew	ATTTAGAAGGTCCATTAGTATATAGTTGC‡	500
<i>speB</i>	MS384	GGCATGTCCGCCTACTTTACCGA	800
	MS385	CAGGTGCACGAAGCGCAGAAG‡	800
<i>speC</i>	MS410	TACTGATTTCTACTATTTACCTATCATC	447
	MS411	TCTGATTTTAAAGTCAATTTCTGG‡	447
<i>speG</i>	MS412	GCTATGGAAGTCAATTAGCTTATGCAG	448
	MS413	CCGATGTATAACGCGATTCCGA‡	448
<i>speI</i>	<i>speI</i> -up	GGTCCGCCATTTTCAGGTAGTT	516
	<i>speI</i> -rew	ACGCATACGAAATCATACCAGTAG‡	516
<i>speJ</i>	MS414	CACTCCTTGTACTAGATGAGGTTGC	508
	MS415	ACGCATACGAAATCATACCAGTAG‡	508
<i>sagBC</i>	sagBC-fw	GCAGCTAGTTGCTCAACATTTAATG	600
	sagBC-rew	CATAGGCAGTGCCTGATTCC‡	600
<i>prtF</i>	MS400	CGGAGTATCAGTAGGACATGCGGA	882
	MS401	CTCCACCAACATTGCTTAATCCA‡	882
<i>PAM</i>	PAM-fw	GCAGACGACGCTAGAAATGAAGTA	900
	PAM-rew	CCTGCTTGTTGGTCTTGACCTTTAC‡	900
<i>sof</i>	MS402	ATGCCTGGTTGGGTATCTTCGGT	406
	MS403	AGAGAACAACGTTCTGCGCCTA‡	406
<i>ssa</i>	ssa-fw	GTAGTCAGCCTGACCCTACTCCAGAAC	621
	ssa-rew	ACTGATCAAATATTGCTGCAGGTGC‡	621
<i>sda1</i>	MS431	GGGTCTATAAGAAAAGTGGGCAAAG	439
	MS432	TGATCGTAAAGGTGGGATGCAGTA‡	439

**slo*, streptolysin O; *speA*, streptococcal pyrogenic toxin A; *speB*, streptococcal cysteine protease; *speC*, streptococcal pyrogenic toxin C; *speG*, streptococcal pyrogenic toxin G; *speI*, streptococcal pyrogenic toxin I; *speJ*, streptococcal pyrogenic toxin J; *sagBC*, streptolysin S-associated gene B/C protein; *prtF*, fibronectin-binding protein; *PAM*, plasminogen-binding protein; *sof*, serum opacity factor; *ssa*, streptococcal superantigen; *sda1*, streptodornase D.
†Primers indicated in **boldface** were created with the VectorNT program (Invitrogen, Carlsbad, CA, USA). Other primers were described by Santagati et al. (11).
‡Reverse primers.

Tab.1: Primers used for identification of virulence genes by PCR for *S.pyogenes* isolates [Santagati M, 2014].

3.4 RNA extraction. Total RNA was isolated from GAS grown to the mid-exponential phase (optical density at 600nm [OD₆₀₀] of 0.4) and to stationary phase (optical density at 600nm [OD₆₀₀] of 1.0). Cells were harvested by centrifugation and the bacterial pellet was re-suspended in 100 µl of diethylpyrocarbonate (DEPC) treated water. 100 µl of lysozyme 20mg/ml (Sigma) was added and incubation continued for 30 min at 37°C. After incubation we added 1ml of TRIZOL Reagent (Life Technologies) and incubation continued for 30 min at RT. After incubation 0.2 ml of chloroform was added per 1 ml of TRIZOL Reagent. The samples were mixed vigorously and then centrifuged at 12,000 × g for 15 min at 4°C. The RNA was precipitated from the aqueous phase by mixing with 0.5 ml of isopropanol. The samples were incubated at room temperature for 10 min and centrifuged at 12,000 ×

g for 10 min at 4°C. The pellet was air dried and dissolved in DEPC treated water. Contaminating genomic DNA was removed from each RNA sample using Turbo DNase (Ambion) and verified by PCR. The RNA was quantitated by A₂₆₀ measurement.

3.5 RT-PCR and qRT-PCR. 10 µg of total RNA was converted into complementary DNA using hex nucleotide primers ImPRO-II Reverse Transcriptase Kit (Promega) according to the manufacturer's instructions. Quantitative real-time PCR assays were performed using QuantiFast Probe Master mix in a Rotor-Gene instrument (QUIAGEN). Transcription of the gyrase subunit A (*gyrA*) was not affected under a variety of *in vitro* experimental conditions hence, *gyrA* expression was used to normalize *in vitro* TaqMan data. TaqMan primers and probes for genes of interest are shown in **Table 2**. Primers and probe (0.25 µM forward and reverse primers and 0.1 µM probe) was prepared, then 0.5 µL of each primer and 0.2 µL of probe were used in a final PCR reaction volume of 20 µL, containing 10 µL of 2X QuantiFast Probe PCR Master Mix (Qiagen, Germany), and 7.8 µL water and 2 µL of the genomic cDNA was added. The thermal profiling of the reaction included an initial denaturation step at 95°C for 4 min followed by 40 cycles of annealing-extension step at 60°C for 30 s. The performance of primer and probe sets was tested using the Rotor-Gene Q system (Qiagen, Germany), and raw data were analyzed by the Rotor-Gene Q Software 2.1.0.9. All experiments were performed in triplicate on two separate days. Expression analyses were performed using the relative expression software tool REST2009 (Relative Expression Software Tool).

GENE	PROBE/PRIMERS	SEQUENCE	FLUOROPHORE
<i>gyrA</i>	gyrA-Tq	ACCACTGAGCCATACGAACCAT	FAM
	gyrA-up Tq	TCGTCGTATTCTCTATGG	
	gyrA-rew Tq	CAAGCATATGGCGATAAC	
<i>covS</i>	covS-Tq	TGCCATACGGTCAGCCTCAT	FAM
	covS-up Tq	GGCATATTGGTCTCTTACA	
	covS-rew Tq	GTACGCGAATCATGTCTA	
<i>covR</i>	covR-Tq	CAACATTAGTCTCAACGGCTTCATCAT	FAM
	covR-up Tq	CGTGAATATGATTTGCTTAA	
	covR-rew Tq	CGGAGATAACGAATATAGAC	
<i>speB</i>	speB- Tq	ATTCTAGGATACTCTACCAGCGGAT	HEX
	speB-up Tq	GAAGCAATGTTTTCTTTACC	
	speB-rew Tq	GAGGATTTGTTATCGTTTCA	
<i>sagA</i>	sagA-Tq	TACAGCAGCAACAGCAGCCT	FAM
	sagA-up Tq	GTAGCTGAAACAACACTCAA	
	sagA-rew Tq	CCAGTAGCAATTGAGAAG	
<i>slo</i>	slo-Tq	CCTTGTTACTGCTAATGCTGAATCG	FAM
	slo-up Tq	GCAGCTCTTATCATTGGTA	
	slo-rew Tq	GTCGTTGTGGTTTCTGTA	
<i>sic</i>	sic-Tq	TAGACCAGCCATATTGAGACCAGA	FAM
	sic-up Tq	CTGGAGATGGTTTGTCTA	
	sic-rew Tq	GGCATTCTTCTTTATCG	
<i>hasA</i>	has-Tq	AGCACAGACCTATCCGTTATCAGAA	FAM
	has-up Tq	GATGCCGAGTCATTATTAG	
	has-rew Tq	CGACAAATATCCACTTCTC	
<i>ska</i>	ska- Tq	AACAGTCAAGTCGGTCCAGC	FAM
	ska-up Tq	ACTGTGTTTGCATTAAC	
	ska-rew Tq	CAGGTTGTGATGTTAGATC	
<i>sda1</i>	Sda1- Tq	AGAGCCACTGAATCCGACTACAAG	FAM
	Sda1-up Tq	GTGGGTGGTATTCTTATTTT	
	Sda1-rew Tq	NCTTCTTCTTAAGCTATCG	
<i>speA</i>	speA- Tq	CCTCCGTAGATACATGGACTCCTT	FAM
	speA-up Tq	TCACGATTTTAATGTTTCA	
	speA-rew Tq	TCCCTTCATGATTTGTTAC	

Tab.2: Primers/Probes used for TaqMan assay

3.6 MV Isolation protocol. MVs were isolated from supernatant culture following the method of Way et al. [Wai S.N, 2003]. Briefly, *S.pyogenes* RM1 strain was

grown in 1 L BHI-medium and cultivated overnight (Optical Density, OD₆₀₀ ~ 0.9/1.0). After removal of the bacterial cells by centrifugation at 3500 rpm for 10 min at 4°, the supernatant fraction was sequentially filtered through 0.45 µm and 0.22 µm vacuum filters (PVDF Millipore) to remove residual bacteria and cellular debris. Preparations of membrane-derived vesicles were checked for absence of bacterial contamination by cultivating small aliquots on blood agar.

The filtered supernatant was then concentrated by ultrafiltration with Stirred Cell Model 8200 (Amicon) using a 100 kDa Ultrafiltration Disc PLHK (Millipore), and was centrifuged at 150,000 x g for 2h at 4° (Beckman L8-70M Ultracentrifuge, SW28 rotor). The pellet was washed with phosphate-buffered saline (PBS), centrifuged again (150,000 x g for 2h at 4°), and resuspended in 200µl of PBS.

3.7 Purification of MVs. Fractionation of MV preparations was performed by density gradient centrifugation essentially as described by H.Chutkan [H.Chutkan, 2013]. OptiPrep (60% stock, Sigma-Aldrich) solution was added to the pellet containing MVs at a ratio of 1:3 (by volume) to adjust the vesicle preparation to 45% OptiPrep. 2 mL of vesicles were pipetted into 45% OptiPrep on the bottom of a 12.5-mL Ultraclear centrifuge tube, and then different Optiprep/HEPES layers were sequentially added as follows: 2 ml 45%, 2 ml 40%, 2 ml 30%, 2 ml 20%, 1ml 15%, and 2 ml 10%. Gradients were centrifuged at 120,000 x g for 4h at 4°C in an SW 41 Ti rotor (Beckman Instruments Inc.), and fractions of equal volumes (2/1 ml) were removed sequentially from the top. The MV fraction of 10%, 15% and 20% and those of 30%, 40% and 45% were pooled together and was added tenfold the sample volume of DPBSS. MV fractions were centrifuged at 38,400 x g for 4h at 4°C to

remove the OptiPrep Solution. Vesicle pellets were resuspended in 200µl of DPBSS (Fig.10).




Fig.10. OMV preparation workflow. (1) Cultivation in liquid media (2) Removal of intact bacteria (3) Concentration of the culture filtrate (4) Purification. Klimentová J, 2014. *Microbiological Research*.




Fig.11. Schematic of ultracentrifuge tubes loaded with the vesicle preparation in the 45% OptiPrep at the bottom of the tube. Halima Chutkan, 2013. *Molecular Biology*, vol. 966.

3.8 Scanning Electron Microscopy (SEM) analysis.

Bacteria for scanning electron microscopy were washed in 0.1 M sodium cacodylate buffer, applied to a poly L-lysine-coated coverslip, fixed with 2.5% glutaraldehyde, dehydrated, sputter coated and viewed on a Philips XL 30 ESEM at 30 kV.

3.9 Transmission Electron Microscopy (TEM) analysis.

The membrane vesicle pellets (20 μ l) were fixed in 60 μ l of 3% formaldehyde at 4°C. A drop (5 μ l) of the above suspension was layered on a formvar-coated copper grid (Electron Microscopy Sciences, Fort Washington, PA) and allowed to dry for 20 min to absorb exosomes. The grids were rinsed side down 2x2 min in PBS, fixed with 2% glutaraldehyde in PBS for 5 min at room temperature, rinsed 2x2 min with water and therefore were negatively stained with 4% uranyl acetate for 5 min and allowed to air dry. The observations were carried out using a Hitachi H-7000 transmission electron microscope (Hitachi High-Technologies Europe GmbH, Krefeld, Germany).

3.10 Dynamic Light Scattering (DLS). DLS measurements were performed with Zetasizer Nano ZS (Malvern, Herrenberg, Germany). Solvent-resistant microcuvettes (ZEN0040, Malvern, Herrenberg, Germany) were used for experiments with a sample volume of 150 μ L. The count rates obtained were then corrected for the attenuator used. For each sample, two measurements were averaged [Palmieri, 2014]

4. Results

4.1 Molecular identification of *emm*-typing and MLST determination

The *emm*-typing determination of all isolates included in our study was conducted by PCR using protocols and the database of the Centers for Disease Control and Prevention (CDC). All three GAS strains were *emm*-type 1 and the analysis of allelic profiles obtained showed that strains RMG1 and CT1 belong to ST28 sequence typing, while strain RM1 is a new single locus variant (slv) of ST28, which was deposited by us on the MLST database and called "ST648" [Santagati M, 2014]. Furthermore, determination of the clonal complex, which was performed using the algorithm eBURST, showed that all strains with ST28/ST648 belong to the Clonal Complex 28 (CC28) [Santagati M, 2014].




Fig.13: Eburst of CC28; *S.pyogenes* RM1

4.2 Determination of antibiotic resistance profiles and virulence gene content

All isolates were susceptible to erythromycin, tetracycline, amoxicillin, penicillin, and clindamycin by Etest (bioMérieux, Marcy l'Etoile, France). Results were interpreted according to the European Committee on Antimicrobial Susceptibility Testing breakpoints (www.eucast.org/clinical_breakpoints) [Santagati M, 2014].

The virulence profile of our isolates was determined by PCR assay and all primers used were designed with the VectorNTI program (Invitrogen, Carlsbad, CA, USA) and are described in **Tab.1**.

To realize our aim, we introduced two different control strains into the study: *S.pyogenes* SF370, belonging to the M1-Type, (GenBank No.AE004092) and the hypervirulent MGAS5005 strain (GenBank No. CP000017.2) with serotype M1T1 responsible for serious invasive infections.

The results obtained showed that the three clinical isolates, RM1, RMG1 and CT1 were identical, in terms of the *spe* genotype (*speA*⁺, *speB*⁺, *speC*⁻, *speG*⁺, *speI*⁻, *speJ*⁺, *smeZ*⁺), to the reference strain MGAS5005 M1T1 and [Santagati, 2014] they were also positive for *sagA* and *sdal*. All the three GAS strains tested demonstrated the absence of *ssa*, *prf* and *sof*; while the SF370 strain was negative for *speA* and *sdal* and positive for *speC* (**Tab.3**).

Strains	emm-type	CC	ST	<i>speA</i>	<i>speB</i>	<i>speC</i>	<i>speG</i>	<i>speJ</i>	<i>speI</i>	<i>sagA</i>	<i>sagBC</i>	<i>smeZ</i>	<i>slo</i>	<i>ssa</i>	<i>sdal</i>	<i>pam</i>	<i>sof</i>	<i>prtF</i>
SF370	M1	28	28															
5005	M1																	
RM1	M1	28	648															
RMG1	M1	28	28															
CT1	M1	28	28															

Tab.3: Virulence gene content of three clinical isolates (black) and two reference control strains (red).

4.3 Gene expression study of some virulence toxins in different growth phases by Real-Time PCR

The expression of virulence genes in GAS is controlled by *covRS* and changes during growth-phase. To investigate gene expression levels of most virulence toxins implicated in GAS infections, we chose three growth phases: OD 0.4 and 1.0 at $A_{600\text{ nm}}$ and O/N time points, which coincide with the exponential phase ($A_{600\text{ nm}} = 0.4$) and the stationary phase ($A_{600\text{ nm}} = 1.0$ & over night, O/N). To check for variation in individual RNA isolations, total RNA was isolated from triplicate cultures at each time point.

To determine the virulence expression profile of our three clinical isolates, we used to different reference strains: SF370 which represents the model of invasive but not aggressive GAS infection; and MGAS5005 strain, a serotype M1T1 organism that is genetically representative of contemporary isolates and that has been used extensively in pathogenesis research.

Our results showed that *covS* and *covR*, a sensor kinase and intracellular regulator of the CovRS system, were downregulated in exponential phase in CT1, RMG1 and SF370 *S.pyogenes* and upregulated in OD:1 phase with exception of SF370 in which expression levels of *covS* remain low during the stationary growth phase, while those of *covR* increase. Instead, levels of *covS/R* transcripts were upregulated both in the model of GAS invasive infections, MGAS5005, which in one of the strains, RM1, which was the clinical isolate that caused a more aggressive infection. RM1 and MGAS5005 strains showed the same behavior with an upregulation of this locus during all growth phases.

The transcription of *speB* and *sagA*, according to other papers [Chuan, Chiang-Ni *et al.*, 2009], was restricted to the stationary phase for all isolates, except for CT1 which always presents low levels of *speB* gene.


In contrast, expression of *slo* was restricted to the exponential phase for all clinical isolates, but not for MGAS5005 and SF370, which downregulated both *slo* and *sic* genes. High levels of *sic* gene were observed in CT1 and RMG1 strains during their exponential phase; during the stationary phase just in CT1 GAS strain a lower expression of *sic* was observed, which remained constant for RMG1 in both phases.

RM1 increased the expression of *sic* gene in the stationary phase with an opposite behavior to the *slo* gene.

The *hasA* gene encodes hyaluronate synthase, which is required for resistance to phagocytosis, and was upregulated during all growth phases just for CT1 and RM1 strains, for the other strains this gene was downregulated. Regarding *ska* gene, we cannot describe significant changes in expression levels of our clinical isolates. An important characteristic of the hypervirulent globally disseminated MIT1 clone of GAS is the presence of two prophage-encoded genes, *sda* and *speA*. We observed high levels of *sda* transcripts in all growth phases and in all our samples of MIT1 GAS, except for RMG1; while the transcription of *speA* was restricted for most of the stationary phase, but not for MGAS5005, which unexpectedly expressed a low level of *speA* gene.

According to our analyses, none of the clinical isolates has an expression profile of virulence determinants comparable to the two different models of GAS strains, SF370 and MGAS5005. In fact, levels of two regulated genes (*covS/covR*) along

with genes encoding the toxins *speB* and *sagA*, greatly increase during their stationary phases for all of our clinical isolates. (fig. 14; Tab. 4)






Fig.14: Study of gene expression of *S.pyogenes* by TaqMan Real-Time PCR;

Strains	<i>covS</i>		<i>covR</i>		<i>speB</i>		<i>sagA</i>		<i>slo</i>		<i>sic</i>		<i>hasA</i>		<i>ska</i>		<i>sda</i>		<i>speA</i>	
	ON/O.4	ON/1	ON/O.4	ON/1	ON/O.4	ON/1	ON/O.4	ON/1	ON/O.4	ON/1	ON/O.4	ON/1	ON/O.4	ON/1	ON/O.4	ON/1	ON/O.4	ON/1	ON/O.4	ON/1
CT1	downregulated	upregulated	downregulated	downregulated	downregulated	downregulated	downregulated	downregulated	upregulated	downregulated	upregulated	downregulated	upregulated	upregulated	no difference	no difference	upregulated	upregulated	downregulated	upregulated
RMG1	downregulated	upregulated	downregulated	upregulated	downregulated	upregulated	downregulated	upregulated	upregulated	upregulated	upregulated	upregulated	downregulated	downregulated	downregulated	downregulated	downregulated	downregulated	downregulated	upregulated
RM1	upregulated	upregulated	upregulated	upregulated	downregulated	upregulated	downregulated	upregulated	downregulated	downregulated	upregulated	upregulated	upregulated	upregulated	no difference	downregulated	no difference	upregulated	upregulated	upregulated
5005	upregulated	upregulated	upregulated	upregulated	downregulated	upregulated	downregulated	upregulated	downregulated	downregulated	downregulated	downregulated	downregulated	downregulated	upregulated	upregulated	upregulated	upregulated	downregulated	downregulated
SF370	downregulated	downregulated	downregulated	upregulated	downregulated	upregulated	downregulated	upregulated	downregulated	no difference	downregulated	downregulated	downregulated	downregulated	upregulated	downregulated				

Legend :  downregulated
 upregulated
 no difference

Tab. 4: Analysis of GAS in vitro transcript levels. Aliquots were removed for RNA extraction at equivalent OD600 values: 0.4; 1.0 and O/N. Relative abundance of CovR/S regulated transcripts determined by TaqMan assays. Data shown are fold changes in transcript (O/N culture strain relative to 0.4 culture and O/N relative to 1.0 culture) normalized to *gyrA* transcript amounts for selected genes.

4.4 Secretion of MVs from Gram positive bacteria, *S.pyogenes*

We investigated the production and release of MVs by *S.pyogenes* RM1, which was the *S.pyogenes* to have a new single locus variant (slv) of ST28. First, we tested whether the bacteria released membranous material into the culture medium by filtering and ultracentrifuging the supernatant when the bacterial culture reached an $OD_{600} = 09/1.0$, which corresponded to the late-stationary phase (fig. 15). In the first step, MVs were isolated using a combination of centrifugation and ultrafiltration to eliminate residual cells and cell debris. In the second step, MVs were purified using OptiPrep gradient density centrifugation to remove protein aggregation. After OptiPrep gradient density, we combined two OptiPrep layer fractions from the bottom to the top of the gradient: 45%, 40% and 30%; 20%, 15% and 10%. We checked the presence of spherical vesicle-like structures in the putative MV fractions by TEM after preparing the samples. In both fractions membrane vesicles were observed with heterogeneous size from 165nm to 800nm. Dynamic Light Scattering analysis of two fractions confirmed heterogeneous size, with a peak of 623 nm for the fractions of 20%, 15% and 10%; (fig. 16 e) while a peak was observed of 800nm for the fractions of 45%, 40% and 30% (fig. 16 e).




Fig. 15: MVs shed from *S.pyogenes*; This scanning electron image by Sem shows the formation of MVs on the cell surface.




Fig. 16: *Spyogens* MVs after Optiprep gradient density; Fractions 20%, 15% and 10% (**a** and **b**); Fractions 45%, 40% and 30% (**c** and **d**); Size distribution of MVs measured with dynamic light-scattering shows the diameter range of 165–800 nm. RM1_2 (green): Fractions 20%, 15% and 10% with a peak of 623nm; RM1_1(red): Fractions 45%, 40% and 30% with a peak of 886nm (**e**).

5. Discussion

Streptococcus pyogenes M1T1 cause a wide variety of human pathological infections ranging from uncomplicated pharyngitis to necrotizing fasciitis and streptococcal toxic shock syndrome. Worldwide, GAS causes an estimated 650,000 invasive infections and 150,000 deaths annually [Carapetis J.R *et al.*, 2005]. Increased reports of severe GAS disease in recent decades have been attributable to the emergence of a new globally-disseminated clone of the M1T1 serotype [Cole JN *et al.*, 2011]. Whereas antibiotic therapy is normally efficient against non-invasive GAS disease, severe *S.pyogenes* group A infections are more complicated to treat because the pathogenesis of *S.pyogenes* group A infections reflects the complex interplay between host and bacteria, depending on production and secretion of several molecules that block phagocytosis, degrade immunoglobulins, inhibit complement activation, and facilitate invasion of human tissue [Cunningham *et al.*, 2000]. Genomic analysis of more than 3600 *S.pyogenes* strains belonging to serotype M1 distinguished two main groups: SF370-like and MGAS5005-like, the latter characterized by a hypervirulent profile related to the acquisition of phage-associated virulence factors by horizontal gene transfer mechanisms [Fiebig A, 2015]. Invasive bacterial disease requires the presence of virulence factors that facilitate the microbe's interactions with host tissues and subvert the defenses of the innate immune system. In the *emm1* GAS clone, progression to systemic infection is also favored by mutations in the two-component *covRS* regulator, which enhance resistance to subepithelial innate immune defenses and facilitate deep-tissue penetration. These mutations markedly alter the transcriptional profiles of invasive GAS isolates compared with those of pharyngeal mucosal isolates [Churchward G *et*

al., 2007] characterized by strongly upregulating *sdal* transcription and markedly downregulating the expression of the gene encoding the cysteine protease *SpeB*.

In the present study, we characterized three clinical isolates of MIT1 GAS clone isolated from different Italian Hospitals evaluating their virulence content, their expression profile in different growth phases and investigating the ability to produce membrane vesicle structures as a new strategy to delivery virulence factors. Analysis of *emm*-typing showed that all GAS isolates (CTI, RMG1 and RM1) belonged to ST28 sequence typing, while strain RM1 showed a new single locus variant (slv) of ST28, which was deposited in the MLST database and called "ST648" [Santagati M, 2014]. First results were consistent with the severity of infections reported by patients, which is typical of GAS MIT1 strains. One important feature of MIT1 clone compared with less pathogenic GAS strains is the acquisition of two prophage encoding *Sda* and *SpeA* toxins. The former has been shown to promote MIT1 GAS virulence via degradation of DNA-based neutrophil extracellular traps (NETs), allowing the bacteria to escape from neutrophils and thus facilitating the spread of bacteria [Buchanan JT *et al.*, 2006]. Moreover, *Sdal* is an essential driving force for *CovR/S* mutation and *SpeB*-switching in some strains. *SpeB* allows accumulation and activation of the broad-spectrum host protease plasmin on the microbial cell surface, thereby promoting infection spread to normally sterile sites. Superantigen *SpeA* also contributes to augmenting dissemination and virulence potential. Analysis of genetic virulence content of the three clinical isolates showed a comparable profile between themselves and to the reference strain MGAS5005, confirming the presence of *sdA*, *speA* and other genes implicated in virulence (**Tab.3**).

The expression profile of the most virulence toxins implicated in GAS infection diseases was obtained by TaqMan Real-Time assay. Our analysis demonstrated that not all of our clinical isolates have the same virulence expression profile despite all belonging to the M1T1 serotype. For CT1 and RMG1 a maximum level of *CovS* transcripts in stationary phase was observed; while RM1 showed similar results to MGAS5005, where the levels of both *CovS* and *CovR* transcripts increased simultaneously to their growth. Indeed, Chuan, Chiang-Ni *et al.* demonstrated that *CovR* expression at the stationary phase was associated to *emm1*/ST28 strains [Chuan, Chiang-Ni *et al.*, 2009]. However, one of the most notable changes in gene expression during bacteria growth is the remarkable downregulation of the major streptococcal protease, *SpeB*, and the consequent increase of most extracellular factors, including *slo*, *sic*, *hasA* and *sda*. In fact, when *SpeB* is normally expressed, it is able to degrade fibronectin, vitronectin to facilitate tissue invasion and spreading within the host [Kapur *et al.*, 1993] and at the same time some virulence toxins are degraded (*Sic*, *M* protein, *Ska*, and *Sda*) maybe to evade initial innate host defenses [Aziz *et al.*, 2008]. Thus, our results, showing an inverse correlation between low transcript levels of *SpeB* and high levels of *hasA*, *sic*, *sda* and *slo* genes, are in agreement with current literature [Nelson C *et al.*, 2011]. In particular, the production of cytotoxin streptolysin O (SLO) prevented internalization of GAS into lysosomes of pharyngeal epithelial cells during the first step of GAS invasion [Sumby P *et al.*, 2005], this may be a reason why, in our clinical isolates, the *slo* gene is highly upregulated during the exponential phase while *speB* is downregulated. Furthermore, we observed that *speB* expression is identical to *sagA* for all of our strains. *SagA* toxins are known to cause epithelial cell cytotoxins, encouraging tissue necrosis

[Engleberg NC *et al.*, 2004], but we do not have an explanation about the correlation between *speB* and *sagA* genes. Besides, all of our isolates showed an upregulation during the stationary phase of *speA* (Tab.4).

Another aim of our study was to evaluate the ability of *S.pyogenes* membrane vesicle production. For many decades, it was assumed that production of membrane vesicles was a capacity just of Gram-negatives, which produced and release vesicles derived from outer membrane [McBroom AJ *et al.*, 2005] and only more recently was discovered in Gram-positive bacteria [Lee EY *et al.*, 2009; Rivera J *et al.*, 2010]. For these reasons, we first investigated whether hypervirulent *S.pyogenes* RM1 was able to produce MVs. When thin sections of GAS RM1 were analyzed with SEM, MVs were clearly visible on the surface of *S. pyogenes*. We also demonstrated, for the first time in this strain, that production and release of MVs were active processes and increased from the late exponential phase to the stationary phase (data not shown). Similarly, MVs shed from *S.pyogenes* were bilayered spherical vesicles. The size range of streptococcal MVs, observed by TEM, were with a heterogeneous size from 165nm to 800nm while Gram-negative OMVs were spherical and bilayered structures with an average diameter of 20–300 nm as described by Beveridge *et al.* [Beveridge *et al.*, 1999]. The size range of MVs of RM1 strain were largerer than we expected, thus, those results were then confirmed by Dynamic Light Scattering analysis and the two fractions of MVs derived from OptiPrep purification, presented two different peaks: 623 nm for the fractions of 20%, 15% and 10%; 800nm for the fractions of 45%, 40% and 30%, in agreement with TEM observations. It has been reported that MVs act as transporters of toxin cargos that are delivered to host cells

[Thay B, *et al.*, 2013], so we can assume that *S.pyogenes* MVs play a role in the delivery of virulence factors to host cells.

In conclusion, studies on possible mutations that occur in CovR/S system are ongoing in our research group because this could increase virulence and pathogenesis of our clinical MIT1 isolates. Furthermore, we have to consider that different severities of disease progression caused by clinical MIT1 isolates depend not only on regulatory gene mutation, but also on host conditions, explaining the remarkably different virulence expression profile of our clinical isolates. Moreover, studies on membrane vesicles of *S.pyogenes* strains will take us one step closer to an integrated view of their functions and compositions as well as applications of these vesicles such as new delivery systems.

6. References

1. **Aas JA, Paster BJ, Stokes LN, Olsen I & Dewhirst FE**, 2005. *Defining the normal bacterial flora of the oral cavity*. J Clin Microbiol 43: 5721–5732.
2. **Akesson P, Sjöholm AG, Biorck L**. 1996. *Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with complement function*. J Biol Chem 271:1081-1088,
3. **Alberti, S., C. D. Ashbaugh, and M. R. Wessels**. 1998. *Structure of the has operon promoter and regulation of hyaluronic acid capsule expression in group A streptococcus*. Mol. Microbiol.
4. **Ashbaugh, C.D., and Wessels, M.R.** 2001. *Absence of a cysteine protease effect on bacterial virulence in two murine models of human invasive group A streptococcal infection*. Infect Immun 69: 6683–6688. (ripetuto due volte)
5. **Ashbaugh, C.D., Warren, H.B., Carey, V.J., and Wessels, M.R.J** *Molecular analysis of the role of the group A streptococcal cysteine protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft tissue infection*. Clin Invest 102: 550–560, 1998
6. **Aziz RK, Ismail SA, Park HW, Kotb**, 2004. *Post-proteomic identification of a novel phage-encoded streptodornase, Sda1, in invasive MIT1 Streptococcus pyogenes*. Mol Microbiol 54: 184–197
7. **Aziz RK, Pabst MJ, Jeng A, Kansal R, Low DE, et al.** 2004. *Invasive MIT1 group A Streptococcus undergoes a phase-shift in vivo to prevent proteolytic degradation of multiple virulence factors by SpeB*. Mol Microbiol 51: 123–134

8. **Aziz, R. K. et al.**, 2010. *Microevolution of group A streptococci in vivo: capturing regulatory networks engaged in sociomicrobiology, niche adaptation, and hypervirulence*. PLoS ONE 5, e9798.
9. **Beres SB, Sylva GL, Barbian KD, et al.** 2000. *Genome sequence of a serotype M3 strain of group A Streptococcus: phage-encoded toxins, the high-virulence phenotype, and clone emergence*. Proc Natl AcadSci USA; 99:10078–83.
10. **Beveridge TJ**, 1999. *Structures of gram-negative cell walls and their derived membrane vesicles*. J Bacteriol; 181:4725–4733
11. **Biagini, Manuela Garibaldi, Susanna Aprea, Alfredo Pezzicoli, Francesco Doro, Marco Becherelli, Anna Rita Taddei, Chiara Tani, Simona Tavarini, Marirosa Mora, Giuseppe Teti, Ugo D’Oro, Sandra Nuti, Marco Soriani, Immaculada Margarit, Rino Rappuoli, Guido Grandi and Nathalie Norais**, May 27, 2015. *S.pyogenes Lipoproteins are released as LMVs*. MCP Papers in Press
12. **Bohach, G.A., Hauser, A.R., and Schlievert, P.M.** 1998 *Cloning of the gene, speB, for streptococcal pyrogenic exotoxin type B in Escherichia coli*. Infect. Immun. 56, 1665 – 1667.
13. **Boutriau, D., Poolman, J., Borrow, R., Findlow, J., Domingo, J.D., Puig-Barbera, J., Baldo’, J. M., Planelles, V., Jubert, A. & other authors**, 2007. *Immunogenicity and safety of three doses of a bivalent (B: 4:p1.19, 15 and B: 4:p1.7-2, 4) meningococcal outer membrane vesicle vaccine in healthy adolescents*. Clin Vaccine Immunol 14, 65–73
14. **Buchanan JT, Simpson AJ, Aziz RK, Liu GY, Kristian SA, et al.**2006. *DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps*. Curr Biol 16: 396–400.

15. Carapetis, J.R., Steer, A.C., Mulholland, E.K. and Weber, M. 2005. *The global burden of group A streptococcal diseases*. Lancet Infect. Dis.
16. Chuan Chiang-Ni, Po-Xing Zheng, Yueh-Ren Ho, Hsiu-Mei Wu, Woei-Jer Chuang, Yee-Shin Lin, Ming-T. Lin, Ching-Chuan Liu, and Jiunn-Jong Wu, 2009. *emm1/Sequence Type 28 Strains of Group A Streptococci That Express covR at Early Stationary Phase Are Associated with Increased Growth and Earlier SpeB Secretion*. Journal of clinical microbiology, Oct. 2009, p. 3161–3169
17. Churchward, G., 2007. *The two faces of Janus: virulence gene regulation by CovR/S in group A streptococci*. Mol. Microbiol. 64, 34–41.
18. Cleary, P., U. Prabu, J. Dale, D. Wexler, and J. Handley, 1992. *Streptococcal C5a peptidase is a highly specific endopeptidase*. Infect. Immun. 60:5219–5223.
19. Cole JN, Barnett TC, Nizet V, Walker MJ. 2011 *Molecular insight into invasive group A streptococcal disease*. Nat Rev Microbiol 9: 724–736.
20. Cole, J.N., McArthur, J.D., McKay, F.C., Sanderson-Smith, M.L., Cork, A.J., Ranson, M., Rohde, M., Itzek, A., Sun, H., Ginsburg, D., et al. 2006. *Trigger for group A streptococcal MIT1 invasive disease*. FASEB J. 20 , 1745 – 1747, .ripetuto due volte)
21. Crater, D.L., van de Rijn, I. 1995 *Hyaluronic acid synthesis operon (has) expression in group A streptococci*. J. Biol. Chem. 270.
22. D., Schwartz, B., Black, C., Todd, J., Elliott, J., Breiman, R., and Facklam, R. 1993. *Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome*. Talkington Infect. Immun. 61, 3369 – 3374. 2000.

23. Dalton, T. L. & Scott, J. R., 2004. *CovS inactivates CovR and is required for growth under conditions of general stress in Streptococcus pyogenes*. *J. Bacteriol.* 186, 3928–3937
24. Daniel C. Nelson, Julia Garbe and Mattias Collin, 2011. *Cysteine proteinase SpeB from Streptococcus pyogenes – a potent modifier of immunologically important host and bacterial proteins*. *Biol. Chem.*, Vol. 392.
25. De Angelis, P. L., J. Papacontantinou, and P. H. Weigel. 1993. *Molecular cloning, identification, and sequence of the hyaluronan synthase gene from group A Streptococcus pyogenes*. *J. Biol. Chem.*,
26. Deatherage BL, et al., 2009. *Biogenesis of bacterial membrane vesicles*. *Mol. Microbiol.* 72:1395–1407
27. Dorward, D.W., Garon, C.F., 1990. *DNA is packaged within membrane derived vesicles of gram-negative but not gram-positive bacteria*. *Appl. Environ. Microbiol.* 56, 1960e1962;
28. Dutta S., B. Iida, A. Takade, Y. Meno, G. B. Nair, and S. Yoshida, 2004. *Release of Shiga toxin by membrane vesicles in Shigella dysenteriae serotype 1 strain and in vitro effects of antimicrobials on toxin production and release*. *Microbiol. Immunol.* 48:965–969
29. Ellen AF, Zolghadr B, Driessen AM, Albers SV, 2010. *Shaping the archaeal cell envelope*. *Archaea* 2010:608243.
30. Engleberg NC, Heath A, Miller A, Rivera C, Di Rita VJ. 2001. *Spontaneous mutations in the CsrRS two-component regulatory system of Streptococcus pyogenes result in enhanced virulence in a murine model of skin and softtissue infection*. *J Infect Dis* 183: 1043–1054

31. **Engleberg NC, Heath A, Vardaman K, DiRita VJ**, 2004. *Contribution of CsrR regulated virulence factors to the progress and outcome of murine skin infections by Streptococcus pyogenes*. *Infect Immun*; 72:623–628
32. **Favier CF, Vaughan EE, De Vos WM, Akkermans AD**, 2002. *Molecular monitoring of succession of bacterial communities in human neonates*. *Appl. Environ. Microbiol.* 68:219-226
33. **Federle, M.J., McIver, K.S., and Scott, J.R.** 1999. *A response regulator that represses transcription of several virulence operons in the group A streptococcus*. *J Bacteriol.* 181: 3649–3657
34. **Feldmesser M, Kress Y, Casadevall A.**, 2001. *Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection*. *Microbiology* 147:2355–2365.
35. **Ferretti JJ, McShan WM, Ajdic D, et al.** 2001. *Complete genome sequence of an M1 strain of Streptococcus pyogenes*. *Proc Natl Acad Sci USA*; 98:4658–63
36. **Fiebig A, Loof TG, Babbar A, Itzek A, Koehorst JJ, Schaap PJ, Nitsche-Schmitz DP.** 2015. *Comparative genomics of Streptococcus pyogenes M1 isolates differing in virulence and propensity to cause systemic infection in mice*. *Int J Med Microbiol* 305(6):532-43
37. **Fiedler T, Köller T, Kreikemeyer B.** 2015. *Streptococcus pyogenes biofilms-formation, biology, and clinical relevance*. *Front Cell Infect Microbiol.*
38. **Findlow, J., Taylor, S., Aase, A., Horton, R., Heyderman, R., Southern, J., Andrews, N., Barchha, R., Harrison, E. & other authors**, 2006. *Comparison and correlation of Neisseria meningitidis serogroup B immunologic assay results and*

- human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac. Infect Immun* 74, 4557–4565
39. **Fiocca R, et al., 1999.** *Release of Helicobacter pylori vacuolating cytotoxin by both a specific secretion pathway and budding of outer membrane vesicles. Uptake of released toxin and vesicles by gastric epithelium. J. Pathol.* 188:220–226
40. **Fischetti, V. A., 1989.** *Streptococcal M protein: molecular design and biological behavior. Clin. Microbiol*
41. **Froehlich, B., Bates, C. & Scott, J., 2009.** *Streptococcus pyogenes CovR/S mediates growth in iron starvation and in the presence of the human cationic antimicrobial peptide LL-37. J. Bacteriol.* 191, 673–677
42. **Gankema, H., J. Wensink, P. A. Guinee, W. H. Jansen, and B. Witholt, 1980.** *Some characteristics of the outer membrane material released by growing enterotoxigenic Escherichia coli. Infect. Immun.* 29:704–713
43. **Graham MR, Smoot LM, Migliaccio CA, Virtaneva K, Sturdevant DE, et al. 2002.** *Virulence control in group A Streptococcus by a two-component gene regulatory system: Global expression profiling and in vivo infection modeling. Proc Natl AcadSci U S A* 99: 13855–13860
44. **Graham MR, Virtaneva K, Porcella SF, Barry WT, Gowen BB, et al. 2005.** *Group A Streptococcus transcriptome dynamics during growth in human blood reveals bacterial adaptive and survival strategies Am J Pathol* 166:455–465
45. **Gryllos I, Levin JC, Wessels MR, 2003.** *The CsrR/CsrS two-component system of group A Streptococcus responds to environmental Mg²⁺. Proc Natl AcadSci U S A* 100: 4227–4232

46. **Gurung M, Moon DC, Choi CW, Lee JH, Bae YC, Kim J, Lee YC, Seol SY, Cho DT, Kim SI, et al.**, 2011; *Staphylococcus aureus produces membrane-derived vesicles that induce host cell death*. PLoS One.6:e27958.
47. **Hakansson, A., Bentley, C.C., Shakhnovic, E.A., Wessel, M.R.**, 2005 *Cytolysin-dependent evasion of lysosomal killing*. Proc. Natl. Acad. Sci. USA.
48. **Heath A, DiRita VJ, Barg NL, Engleberg NC** ,1999. *A two-component regulatory system, CsrR-CsrS, represses expression of three Streptococcus pyogenes virulence factors, hyaluronic acid capsule, streptolysin S, and pyrogenic exotoxin B*. Infect Immun; 67:5298–5305
49. **Hoekstra, D., J. W. van der Laan, L. de Leij, and B. Witholt.**,1976. *Release of outer membrane fragments from normally growing Escherichia coli*. 1976. Biochim. Biophys. Acta 455:889–899;
50. **Horstaman and Kuehn**, 2002. *Bacterial surface association of heat-labile enterotoxin through lipopolysaccharide after secretion via the general secretory pathway*. J. Biol. Chem.
51. **Horstman, A. L., and M. J. Kuehn.**, 2000. *Enterotoxigenic Escherichia coli secretes active heat-labile enterotoxin via outer membrane vesicles*. J. Biol. Chem. 275:12489–12496
52. **J., Nomizu, M., Takebe, S., Menard, R., Griffith, D., and Ziomek, E.** 1999. *Autocatalytic processing of the streptococcal cysteine protease zymogen: processing mechanism and characterization of the autoproteolytic cleavage sites*. Doran. Eur. J. Biochem. 263 , 145 – 151

53. **Ji, Y., L. McLands borough, A. Kondagunta, and P. P.**1996.*C5a peptidase alters clearance and trafficking of group A streptococci by infected mice.* Cleary.Infect. Immun. 64:503–510.
54. **Ji, Y., N. Schnitzler, E. DeMaster, and P. Cleary.**1998 *Impact of M49, Mrp, Enn, and C5a peptidase proteins on colonization of the mouse oral mucosa by Streptococcus pyogenes.* Infect. Immun. 66:5399–5405.
55. **Kadurugamuwa, J. L., and T. J. Beveridge.J.,** 1995. *Virulence factors are released from Pseudomonas aeruginosa in association with membrane vesicles during normal growth and exposure to gentamicin: a novel mechanism of enzyme secretion.* Bacteriol. 177:3998–4008.
56. **Kansal, R. G., Nizet, V., Jeng, A., Chuang, W. J. &Kotb,** 2003. *Selective modulation of superantigen-induced responses by streptococcal cysteine protease.* M. J. Infect. Dis. 187, 398–407.
57. **Kansal, R., McGeer, A., Low, D., Norrby-Teglund, A., and Kotb, M.** *Inverse relation between disease severity and expression of the streptococcal cysteine protease, SpeB, among clonal MIT1 isolates recovered from invasive group A streptococcal infection cases.* Infect. Immun. 68, 6362–6369 , ripetuto due volte)
58. **Kapur V, Majesky MW, Li LL, Black RA, Musser JM ,** 1993.*Cleavage of interleukin 1 beta (IL-1 beta) precursor to produce active IL-1 beta by a conserved extracellular cysteine protease from Streptococcus pyogenes.* ProcNatl AcadSci U S A 90: 7676–7680
59. **Kapur, V., Topouzis, S., Majesky, M., Li, L.-L., Hamrick, M., Hamill, R., Patti, J., and Musser, J.,** 1993. *A conserved Streptococcus pyogenes extracellular cysteine*

protease cleaves human fibronectin and degrades vitronectin. Microb. Pathog. 15, 327 – 346.

60. **Kazmi SU, Kansal R, Aziz RK, Hooshdaran M, Norrby-Teglund A, et al.** 2001. *Reciprocal, temporal expression of SpeA and SpeB by invasive MIT1 group A streptococcal isolates in vivo.* Infect Immun 69: 4988–4995
61. **Kulp A, Kuehn MJ,**2010. *Biological functions and biogenesis of secreted bacterial outer membrane vesicles.* Annu Rev Microbiol.; 64:163–184
62. **Lancefield, r.c.,** 1933. *A serological differentiation of human and other groups of haemolytic streptococci.* J. Exp Med.
63. **LaPenta, D., X. P. Zhang, and P. P. Cleary.**1994. *Streptococcus pyogenes type IIa IgG Fc receptor expression is co-ordinately regulated with M protein and streptococcal C5a peptidase* Mol. Microbiol. 12:873–879.
64. **Lee EY, et al.,** 2009. *Gram-positive bacteria produce membrane vesicles:proteomics-based characterization of Staphylococcus aureus-derived membrane vesicles.* Proteomics 9:5425–5436
65. **Levin, J., and M. R. Wessels.**1998. *Identification of csrR/csrS, a genetic locus that regulates hyaluronic acid capsule synthesis in group A streptococcus* Mol. Microbiol.
66. **Liu, T.-Y. and Elliott, S. J.**1965. *Streptococcal proteinase: the zymogen to enzyme transformation.* Biol. Chem. 240 , 1138 – 1142
67. **Loeb MR. J.** 1974. *Bacteriophage T4-mediated release of envelope components from Escherichia coli* Virol. 13:631– 641
68. **Lukomski, S., Burns, E., Wyde, P., Podbielski, A., Rurangirwa, J. Moore-Poveda, D., and Musser, J.**1998. *Genetic inactivation of an extracellular cysteine*

protease (SpeB) expressed by Streptococcus pyogenes decreases resistance to phagocytosis and dissemination to organs. Infect. Immun. 66 , 771 – 776.(ripetuto due volte)

69. **Lukomski, S., Montgomery, C.A., Rurangirwa, J., Geske, R.S., Barrish, J.P., Adams, G.J., and Musser, J.M.** 1999.*Extracellular cysteine protease produced by Streptococcus pyogenes participates in the pathogenesis of invasive skin infection and dissemination in mice* Infect. Immun. 67 , 1779 – 1788
70. **Lukomski, S., Sreevatsan, S., Amberg, A., Reichardt, W., Woischnik, M., Podbielski, A., and Musser, J. J,** 1997. *Inactivation of Streptococcus pyogenes extracellular cysteine protease significantly decreases mouse lethality of serotype M3 and M49 strains.* Clin. Invest. 99, 2574 – 2580.
71. **M., Dorobantu, L., Gray, M. R., Curtis, M. A. & Feldman, M. F,** 2011. *Selective sorting of cargo proteins into bacterial membrane vesicles.* Haurat, M. F., Aduse-Opoku, J., Rangarajan, J Biol Chem 286, 1269–1276;
72. **Madeleine w. Cunningham,** July 2000. *Pathogenesis of Group A Streptococcal Infections.* Clinical microbiology reviews.
73. **Marsollier L, et al.,** 2007. *Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis.* PLoS Pathog. 3:e62.
74. **McBroom AJ, Kuehn MJ,** 2005. *Outer membrane vesicles.* In Finlay BB (ed), *EcoSal—Escherichia coli and Salmonella: cellular and molecular biology.* ASM Press, Washington, DC

75. **McBroom, A. J., and M. J. Kuehn.**, 2007. *Release of outer membrane vesicles by Gram-negative bacteria is a novel envelope stress response.* Mol. Microbiol. 63:545–558
76. **Mercier R, Dominguez-Cuevas P, Errington J.** 2012. *Crucial role for membrane fluidity in proliferation of primitive cells.* Cell Rev. 938; 1:417–23.
77. **Musser JM, Krause RM.** In: **Krause RM, 1998.** *The revival of group A streptococcal diseases, with a commentary on staphylococcal toxic shock syndrome.* ed. Emerging infections. Academic Press,:185–218
78. **Necchi V, et al.**, 2007. *Intracellular, intercellular, and stromal invasion of gastric mucosa, preneoplastic lesions, and cancer by Helicobacter pylori* Gastroenterology 132:1009 –1023
79. **Nobbs AH, Lamont RJ and Jenkinson HF,** 2009. *Streptococcus adherence and colonization.* Microbiol. Mol. Bio. Rev. 73:407-450
80. **Nobbs, A.H, Lamont, R.J. and Jenkinson, H.F,** 2009. *Streptococcus adherence and colonization.* Microbiol. Mol. Biol. Rev
81. **Norrby-Teglund, A., M. Norgren, and S. E. Holm.**1994. *Similar cytokine induction profiles of a novel streptococcal exotoxin, MF, and pyrogenic exotoxins A and B.* Infect. Immun.
82. **Ochman H, Lawrence JG, Groisman EA.** 2000. *Lateral gene transfer and the nature of bacterial innovation.* Nature;405:299–304,
83. **Olaya-Abril A, et al,** 2014. *Characterization of protective extracellular membrane-derived vesicles produced by Streptococcus pneumoniae,* J Prot.
84. **Oliveira DL, et al ,**2010. *Biogenesis of extracellular vesicles in yeast: many questions with few answers.* Commun. Integr. Biol. 3:533–535

85. **Paul Sumby, Steve F. Porcella, Andres G. Madrigal, a Kent D. Barbian, Kimmo Virtaneva, Stacy M. Ricklefs, Daniel E. Sturdevant, Morag R. Graham, Jaana Vuopio-Varkila, Nancy P. Hoe, and James M. Musser** .2005. *Evolutionary Origin and Emergence of Highly Successful Clone of Serotype M1 Group A Streptococcus Involved Multiple Horizontal Gene Transfer Events*. The Journal of infection disease.
86. **Pence, M. A. et al., 2010**. *Streptococcal inhibitor of complement promotes innate immune resistance phenotypes of invasive MIT1 group A Streptococcus* J. Innate Immun. 2, 587–595.
87. **Raeder R, Woischnik M, Podbielski A, Boyle MD, 1998**. *A secreted streptococcal cysteine protease can cleave a surface-expressed M1 protein and alter the immunoglobulin binding properties*. Res Microbiol 149: 539–548
88. **Ramy K. Aziz and Malak Kotb, 2008**. *Rise and Persistence of Global MIT1 Clone of Streptococcus Pyogenes*. Emerging Infectious Diseases
89. **Rasmussen M, Bjorck L, 2002**. *Proteolysis and its regulation at the surface of Streptococcus pyogenes*. Mol Microbiol 43: 537–544
90. **Ringdahl, U. et al. 2000**. *A role for the fibrinogen-binding regions of streptococcal M proteins in phagocytosis resistance*. Mol. Microbiol. 37, 1318–1326.
91. **Rivera J, et al, 2010**. *Bacillus anthracis produces membrane-derived vesicles containing biologically active toxins*. Proc. Natl. Acad. Sci.U. S. A. 107:19002–19007;
92. **Ronan K. Carroll and James M. Musser. 2011** *From transcription to activation: how group A streptococcus, the flesh-eating pathogen, regulates SpeB cysteine protease production*. Molecular Microbiology. 81(3), 588–601.

93. **S. Berge, A. and Bjrck, L. J.** 1995. *Streptococcal cysteine proteinase releases biologically active fragments of streptococcal surface proteins.* Biol. Chem. 270, 9862– 9867
94. **Santagati Maria, Teresa Spanu, Marina Scillato, Rosaria Santangelo, Fabio Cavallaro, Vincenzo Arena, Giacomo Castiglione, Marco Falcone, Mario Venditti, and Stefania Stefani.** 2014. *Rapidly Fatal Hemorrhagic Pneumonia and Group A Streptococcus Serotype M.* Emerging Infectious Diseases. Vol. 20, No. 1.
95. **Sawai, J. et al,** 2007. *Growth phase-dependent effect of clindamycin on production of exoproteins by Streptococcus pyogenes.* .Antimicrob. Agents Chemother. 51, 461– 467.
96. **Schooling SR, Beveridge TJ J.,** 2006. *Membrane vesicles: an overlooked component of the matrices of biofilms.* Bacteriol. 188:5945–5957
97. **Schrager, H. M., S. Alberti, C. Cywes, G. J. Dougherty, and M. R. Wessels. J.**1998. *Hyaluronic acid capsule modulates M protein-mediated adherence and acts as a ligand for attachment of group A streptococcus to CD44 on human keratinocytes.* Clin. Investig.
98. **Shannon, J. G., Ross, C. L., Koehler, T. M. & Rest, R. F.** 2003. *Characterization of anthrolysin O, the Bacillus anthracis cholesterol-dependent cytolysin.* Infect. Immun
99. **Shepard, L. A., Shatursky, O., Johnson, A. E. & Tweten, R. K,** 2000 *Insights into the action of the superfamily of cholesterol-dependent cytolysins from studies of intermedilysin.* Biochemistry.

100. **Sibbald, M. J., Ziebandt, A. K., Engelmann, S., Hecker, M. et al.**, 2006. *Mapping the pathways to staphylococcal pathogenesis by comparative secretomics*. Microbiol. Mol. Biol. Rev. *70*, 755–788.
101. **Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, Casanueva GV, Rico CO, Rodriguez CR, Terry MH.** 1991. Vaccine against group B *Neisseria meningitidis*: protection trial and mass vaccination results in Cuba. NIPH annals **14**:195-207; discussion 208-110.
102. **Silverman JM, et al.**, 2008. *Proteomic analysis of the secretome of Leishmania donovani*. Genome Biol. **9**:R35.82;
103. **Silverman JM, et al.**, 2010. *An exosome-based secretion pathway is responsible for protein export from Leishmania and communication with macrophages*. J. Cell Sci. **123**:842– 852
104. **Smoot JC, Barbian KD, Van Gompel JJ, et al.** 2002. *Genome sequence and comparative microarray analysis of serotype M18 group A Streptococcus strains associated with acute rheumatic fever outbreaks*. Proc Natl AcadSci USA; Proc **99**:4668–73.
105. **Stevens DL, Salmi DB, McIndoo ER, Bryant AE. Bryant AE.** , 2000. *Molecular epidemiology of nga and NAD glycohydrolase/ADP-ribosyltransferase activity among Streptococcus pyogenes causing streptococcal toxic shock syndrome*. J Infect Dis; **182**:1117–28.
106. **Sumby P, Barbian KD, Gardner DJ, et al.**, 2005. *Extracellular deoxyribonuclease made by group A Streptococcus assists pathogenesis by enhancing evasion of the innate immune response*. Proc Natl Acad Sci USA; **102**:1679–84.

107. **Sumby P, Whitney AR, Graviss EA, DeLeo FR, Musser JM.** 2006. *Genome-wide analysis of group A streptococci reveals a mutation that modulates global phenotype and disease specificity.* PLoS Pathog 2: e5.
108. **Sun, H. et al.** 2004. *Plasminogen is a critical host pathogenicity factor for group A streptococcal infection.* Science 305, 1283–1286, **A report showing that human plasminogen is activated to plasmin on the GAS cell surface allowing the destruction of host tissue barriers and triggering systemic spread.**
109. **Svensson MD, Scaramuzzino DA, Sjobring U, Olsen A, Frank C, et al,** 2000. *Role for a secreted cysteine proteinase in the establishment of host tissue tropism by group A streptococci.* MolMicrobiol 38: 242–253.
110. **Tagg John R, Dierksen Karen P,** 2003. *Bacterial replacement therapy: adapting ‘germ warfare’ to infection prevention.* ELSEVIER. 21:217-223
111. **Tagg JR, Pybus V et al,** 1983. *Application of inhibitor typing in a study of the transmission and retention in the human mouth of the bacterium Streptococcus salivarius.* Arch Oral Biol 28(10):911– 915
112. **Tart, A.H., Walker, M.J. and Musser, J.M** 2007, *New understanding of group A streptococcus pathogenesis cycle.* Trends Microbiol.
113. **Thay B, Wai SN, Oscarsson J.** 2013. *Staphylococcus aureus alpha-toxin-dependent induction of host cell death by membrane-derived vesicles.* PLoS One;8:e54661
114. **Theresa L.Lamagni,** July 2008. *Epidemiology of Severe Streptococcus pyogenes Disease in Europe.* Journal of clinical microbiology.
115. **Timmer, A.M. et al.** 2009. *Streptolysin O promotes group A Streptococcus immune evasion by accelerated macrophage apoptosis.* J. Biol.Chem.284,862-871

116. **Trevino, J. et al., 2009.** *CovS* simultaneously activates and inhibits the CovR-mediated repression of distinct subsets of group A *Streptococcus* virulence factor-encoding genes. *Infect. Immun.* 77, 3141–3149
117. **Vasilyeva, N. V., Tsfasman, I. M., Suzina, N. E., Stepnaya, O. A. & Kulaev, I. S., 2008.** Secretion of bacteriolytic endopeptidase L5 of *Lysobacter* sp. *XL1* into the medium by means of outer membrane vesicles. *FEBS J* 275, 3827–3835.
118. **Virtaneva K, Graham MR, Porcella SF, et al.** Group A *Streptococcus* gene expression in humans and cynomolgus macaques with acute pharyngitis. *Infect Immun*; 71:2199–207, 2003.
119. **Voyich JM, Sturdevant DE, Braughton KR, et al.** 2003. Genome-wide protective response used by group A *Streptococcus* to evade destruction by human polymorphonuclear leukocytes. *Proc Natl Acad Sci USA*; 100:1996
120. **Wai SN, Lindmark B, Soderblom T, Takade A, Westermark M, et al., 2003.** Vesicle-mediated export and assembly of pore-forming oligomers of the enterobacterial *ClyA* cytotoxin. *Cell* 115: 25–35.
121. **Walker MJ, Hollands A, Sanderson-Smith ML, Cole JN, Kirk JK, et al., 2007.** DNase *SdaI* provides selection pressure for a switch to invasive group A streptococcal infection. *Nat Med* 13: 981–985
122. **Wei L, Pandiripally V, Gregory E, Clymer M, Cue D, 2005.** Impact of the *SpeB* protease on binding of the complement regulatory proteins factor H and factor H-like protein 1 by *Streptococcus pyogenes*. *Infect Immun* 73: 2040–2050
123. **Wescombe PA, Heng NCK, Burton JP and Tagg JR, 2010.** *Something Old and Something New: An Update on the Amazing Repertoire of Bacteriocins Produced by Streptococcus salivarius*. *Probiotics & Antimicro. Prot.* 2:37-45

124. **Wessels, M. R., and M. S. Bronze,** 1994. *Critical role of the group A streptococcal capsule in pharyngeal colonization and infection in mice.* Proc. Natl. Acad. Sci.
125. **Wexler, D.E. and Cleary, P.P.,** 1985. *Purification and characteristic of the streptococcal chemotactic factor inactivator.* Infect. Immun. 50, 757.
126. **Williams, J. N., Skipp, P. J., Humphries, H. E., Christodoulides, M., O'Connor, C. D. & Heckels, J. E.,** 2007. *Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant.* Infect Immun 75, 1364–1372
127. **Woischnik, M., Buttaro, B., and Podbielski, A.** 2000. *Inactivation of the cysteine protease SpeB affects hyaluronic acid capsule expression in group A streptococci.* Microb. Pathog. 28, 221 – 226.
128. **Yu, C.-N. and Ferretti, J,** 1991. *Frequency of the erythrogenic toxin B and C genes and C genes (speB and speC) among clinical isolates of group A streptococci.* Infect. Immun. 59, 211 – 215



Colonization, safety, and tolerability study of the *Streptococcus salivarius* 24SMBc nasal spray for its application in upper respiratory tract infections

M. Santagati¹ · M. Scillato¹ · N. Muscaridola¹ · V. Metoldo¹ · I. La Mantia² · S. Stefani¹

Received: 26 May 2015 / Accepted: 8 July 2015
© Springer-Verlag Berlin Heidelberg 2015

Abstract *Streptococcus salivarius*, a non-pathogenic species and the predominant colonizer of the oral microbiota, finds a wide application in the prevention of upper respiratory tract infections, also reducing the frequency of their main pathogens. In this pilot study, the primary objective was to evaluate the safety and tolerability of a nasal spray, *S. salivarius* 24SMBc, as a medical device in a clinical study involving 20 healthy adult subjects. The secondary aim was to determine the ability of colonization assessed by molecular fingerprinting. Twenty healthy adult subjects, aged between 30 and 54 years, without a medical history of recurrent otitis media, were enrolled. All patient characteristics fulfilled the inclusion criteria. All subjects were treated daily for 3 days with the nasal spray containing *S. salivarius* 24SMBc at a concentration of 5×10^9 colony-forming units (CFU)/ml. The persistence of *S. salivarius* in the nasopharynx was investigated by the antagonism test and random amplified polymorphic DNA polymerase chain reaction (RAPD-PCR). The tolerability and safety were clinically assessed by clinical examinations during treatment. Our results demonstrate the capability of *S. salivarius* 24SMBc to colonize the rhinopharynx tissues in 95 % of subjects and persist in 55 % of them after 6 days from the last dose of the formulation, maintaining a concentration of 10^5 CFU/ml. The treatment was well tolerated by all healthy patients and no adverse effects were found. The

topical application of streptococcal probiotics is a relatively undeveloped field but is becoming an attractive approach for both prevention and therapy, especially for pediatric age patients. *S. salivarius* 24SMBc possess characteristics making this strain suitable for use in bacteriotherapy.

Introduction

In recent years, there has been increasing evidence indicating beneficial effects of probiotics in the prevention and treatment of many diseases, especially in the gastrointestinal tract, preserving intestinal epithelium by maintaining its microbiota and modulating immune response [1–4]. Until now, few studies have been addressed to the use of probiotic strains in upper respiratory tract infections (URTIs) and some studies suggested clinical advantages for the host after probiotic administration [5–7]. The strategy of using a bacterial species belonging to the healthy human oral microbiota as an oral probiotic for URTIs offers great benefits for the host, contributing to the recolonization process, re-establishing microbial balance, and reducing the level of potential pathogens. As regards to potential pathogens, *Streptococcus salivarius* species is considered the predominant “safe” colonizer, capable of fostering a more balanced, health-associated oral microbiota, interfering with potential pathogens; thanks to these characteristics, it is suitable for use as an oral probiotic [8]. Nasopharyngeal colonization plays an essential role in the pathogenesis of URTIs and, in particular, in recurrent acute otitis media (rAOM), acting as a reservoir for mainly respiratory pathogens, such as *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis* [9, 10]. Rebalance of the nasopharyngeal microbiota is a new strategy for the prevention of AOM based on the interaction and competition between potentially pathogenic and commensal bacteria. The

✉ M. Santagati
m.santagati@unicat.it

¹ LabMMAR, Department of Biomedical and Biotechnological Sciences, Section of Microbiology, University of Catania, Via Androne 81, 95124 Catania, Italy

² Department of Medical Sciences, Surgical and Advanced Technologies, GF Ingrassia, University of Catania, Catania, Italy

alteration of the nasopharyngeal microbiota and the absence or the low concentration of α -hemolytic streptococci may correlate with the recurrence of acute episodes [11, 12].

The first clinical use of oral streptococcal probiotics concerning treatment of halitosis and/or *S. pyogenes* infections was reported by Tagg and co-workers, attributing this ability to the presence of *S. salivarius* K12, belonging to the normal commensal flora of the nasopharynx and producer of the *salaB* bacteriocin that is responsible for the inhibition of *S. pyogenes* species [13, 14].

Our group has already studied a strain of *S. salivarius*, 24SMBc (DSM23307), selected from a healthy child [15], for its probiotic characteristics and for its remarkable ability to interfere with URTI pathogens. In particular, this strain can be used as an excellent application in the prevention of rAOM in infants and children, having a strong inhibitory capacity versus *S. pneumoniae*, one of the main pathogens responsible for rAOM [15]. It is well known that rAOM is the most common infection in children, responsible for most antibiotic prescriptions in early childhood. Over 80 % of children experience at least one episode in the first three years of life and about a third has three or more episodes [16]. The treatment of AOM has a significant impact on child health, healthcare costs, and the development of antimicrobial resistance. In only 10–20 % of children can AOM result in recurrence and/or persistence with complications, such as impaired hearing, behavior disorders, and surgical interventions [17].

The main aim of this pilot study was to evaluate the safety, the human tolerability, and persistence of *S. salivarius* 24SMBc, used as a new nasal spray formulation.

Materials and methods

Study design

The objective of this pilot study (performed from 2011 to 2012) was to evaluate the safety and tolerability of *S. salivarius* 24SMBc nasal spray used as a medical device and its ability to colonize and persist in the human rhinopharynx of healthy patients. Twenty healthy adult volunteers, aged between 30 and 54 years, including male and female subjects (12 male and 8 females), without a medical history of recurrent otitis media, were enrolled after informed signed was obtained. The nasal spray formulation contains *S. salivarius* 24 SMBc at a concentration of 1×10^9 suspended in a water solution with dimethicone, without gas. The product was tested preliminarily for its stability at 25 °C and at 4 °C for 1 month, confirming the original concentration. All patients were treated with cefpodoxima (200 mg twice daily for 6 days) before the nasal spray administration, to reduce the level of other oral streptococci and to favor 24SMBc colonization. The nasal spray was administered four times per day at

intervals of about 4 h (concentration per day 8×10^9) for 3 days, excluding the night, by two puffs in each nostril. The study protocol was approved by the ethical committee of L'Unità Operativa Complessa (UOC) di Otorinolaringoiatria—ASP 3 CT, P.O. Acireale, Italy. Because of the safety assessment of the study, our ethical committee suggested only an adult patient population. This study was conducted according to the principles of the Helsinki Declaration (protocol no. MED/SEC/2011/1; rev. 01del 05/07/2011).

Patient selection

The subjects enrolled in this study met the following inclusion criteria: aged between 30 and 54 years old of both sexes and healthy.

Exclusion criteria were: morphofunctional disorders of the nasal passages with intranasal airflow predisposing conditions such as to determine the genesis of inflammatory diseases; objective endoscopic mucosal atrophy and obvious deficit of mucociliary clearance; vasomotor hypertrophic inflammatory diseases, both type-specific and non-specific; metabolic diseases (diabetes), cystic fibrosis, asthma gastroesophageal reflux; a clinical history of recurrent inflammation and/or recurrent URTIs; rhinosinus inflammatory and/or acute oropharyngeal diseases; already using inhaled treatment and/or antibiotics in the 30 days prior to enrollment; treated with immunosuppressants; suffering from chronic renal failure; hypersensitive to cephalosporins; and patients who were pregnant and/or lactating.

Microbiologic analysis of samples

The microbiologic evaluation was performed by rhinopharyngeal (inferior nasal turbinates) swabs obtained after antibiotic treatment (T_0) and at 2 h, 4 h, 24 h, and after 6 days of nasal spray treatment, labeled as T_1 , T_2 , T_3 , and T_4 , respectively. Each rhinopharyngeal swab was plated directly onto Columbia Agar Base (Oxoid, Basingstoke, UK), plus 5 % horse blood to determine the total microflora, and onto Mitis Salivarius Agar (Difco Laboratories), a selective medium for α -hemolytic streptococci. Cultures were incubated overnight at 37 °C in 5 % CO_2 air atmosphere. In addition, all swabs were cultured to determine the presence of other pathogens according to standard laboratory procedures.

Test for antagonism activity and molecular fingerprinting

To evaluate the presence of *S. salivarius* 24SMBc, each morphologically distinct colony grown in Mitis Salivarius Agar was tested for bacteriocin-like inhibitory substance (BLIS) production using a deferred antagonism test [18]. The indicator strains were representative strains of URTIs including AOM pathogens [15]. The molecular fingerprinting of

S. salivarius 24 SMBc was performed on each BLIS-positive colony. The profile was performed by random amplified polymorphic DNA (RAPD) analysis using primers as described previously [19].

Clinical assessments

The clinical evaluation was performed by examination using a rhinolaryngoscope (Pentax FNL-10RP3) through both nasal cavities and by rhinomanometry (Rhinospir PRO, Sibel, Barcelona, Spain). The endoscopic examination (Fig. 1: patient 13, endoscopic evaluation post-treatment) by this method was evaluated as normal by the examination of trophism and the color of the mucous membranes of the whole rhinopharyngolaryngeal tract, as well as the presence and characteristics (hyper or normal morphology) of any secretions (serum or purulent) throughout the upper airway [20, 21].

Safety determination of the preparation was assessed on the basis of objective assessment and on the analysis of the following clinical parameters: body temperature (measured in the morning); blood sample for testing of inflammatory markers [white blood cell count, platelet count, VES, polymerase chain reaction (PCR)]; intensity of any symptoms (runny nose, sneezing, cough) as subjectively perceived according to the Jackson score (0–3); recording of headache, myalgia, and earache.

Results

Safety and tolerability of *S. salivarius* 24SMBc nasal spray formulation

All subjects reported no symptoms associated with the nasal spray administration (runny nose, sneezing, coughing, headache). Side effects and/or undesirable effects were not




Fig. 1 Endoscopic evaluation post-treatment of patient 13 performed using a rhinolaryngoscope (Pentax FNL-10RP3) through both nasal cavities

observed at all. The body temperature (measured in the morning) showed no clinically significant changes, and inflammatory markers did not change after treatment with inhalation of the product in any of the volunteers enrolled in the study. Physical examination of the upper airway showed no signs of infectious diseases throughout endoscopic surveillance.

Microbiological evaluation and colonization

A total of 100 samples (T_0 , T_1 , T_2 , T_3 , T_4) from the 20 subjects were analyzed. All samples were negative at T_0 (i.e., after antibiotic treatment), with the exception of 001 and 009, which were colonized with *S. aureus* (about 50 CFU/ml). The averages of the total microflora population determined on Columbia blood agar after 2 h, 4 h, 24 h, and 6 days from nasal spray administration were approximately from 20 to $>10^6$ CFU/ml for all samples, while on Mitis Salivarius Agar, it was approximately from 10 to 10^4 CFU/ml; only very few samples showed no growth of α -hemolytic streptococci on Mitis Salivarius Agar (Table 1). In addition, samples 001 and 009 at T_3 and T_4 were colonized with *S. aureus*, at low concentrations, remaining unchanged with respect to T_0 (i.e., 50 CFU/ml) and samples 002, 012, 013, and 015 at T_4 were colonized with coagulase-negative staphylococci (CoNS) at bacterial concentrations of approximately from 30 to 100 CFU/ml. The staphylococcal colonization could have interfered with the streptococcal adhesion processes.

The deferred antagonism test to evaluate BLIS_S production and RAPD-PCR analysis for molecular genotyping were applied to each α -hemolytic streptococcal colony to determine the level of colonization of the specific *S. salivarius* 24SMB in the human upper respiratory tract of the volunteers.

The same colonies, showing typical characteristics of *S. salivarius* 24SMBc, i.e., large, soft, and pale blue, were analyzed by the antagonism test against *S. pyogenes* and *S. pneumoniae* groups [15]. All strains tested showed the same *S. salivarius* 24SMB inhibitory activity profile, i.e., strong activity against *S. pneumoniae* and *S. pyogenes*, and no inhibition of oral streptococci. All streptococcal colonies with a positive antagonism test, assayed by RAPD analysis, provided a unique fragment pattern typical of our *S. salivarius* genotype.

Figure 2 shows that the genomic profiles obtained by both OPA3 and OPA18 were identical for all colonies tested.

All these results confirmed that 19 out of 20 patients (95 %) were colonized at least in the first 4 h after nasal spray administration, and 11 out of 20 (55 %) colonizations persisted for at least 6 days from the last dose of the formulation.

Table 1 Levels of *Streptococcus salivarius* 24SMBc colonization over time (2 h to 6 days)

Patient	Age (years)	Bacteria count (CFU/ml)	T ₁ , 2 h	T ₂ , 4 h	T ₃ , 24 h	T ₄ , 6 days	Persistence of <i>S. salivarius</i> 24SMBc at various times
001	45	Total count	>10 ⁶	>10 ⁵	>10 ⁶	>10 ⁶	–
		α-hemolytic streptococci count	65	10	10 ⁴	10 ⁴	T ₁ , T ₂
002	20	Total count	>10 ⁶	10 ²	3 × 10 ²	10 ⁵	–
		α-hemolytic streptococci count	10 ³	20	–	–	T ₁ , T ₂
003	18	Total count	>10 ⁶	>10 ⁶	>10 ⁶	>10 ⁶	–
		α-hemolytic streptococci count	50	30	10 ²	10 ²	T ₁ , T ₂ , T ₃ , T ₄
004	28	Total count	>10 ⁶	>10 ⁶	>10 ⁶	>10 ⁶	–
		α-hemolytic streptococci count	30	10	10	20	T ₁ , T ₂ , T ₃ , T ₄
005	19	Total count	>10 ⁶	>10 ⁶	>10 ⁶	>10 ⁶	–
		α-hemolytic streptococci count	10 ²	40	50	30	T ₁ , T ₂ , T ₃ , T ₄
006	26	Total count	2 × 10 ²	>10 ⁶	20	50	–
		α-hemolytic streptococci count	50	4 × 10 ²	10	10	T ₁ , T ₂
007	24	Total count	>10 ⁶	>10 ⁶	10 ⁴	>10 ⁶	–
		α-hemolytic streptococci count	10 ⁴	10 ³	10 ²	10 ³	T ₁ , T ₂ , T ₃ , T ₄
008	54	Total count	>10 ⁶	10 ⁴	>10 ⁶	>10 ⁶	–
		α-hemolytic streptococci count	10 ⁴	10 ³	10 ³	10 ²	T ₁ , T ₂ , T ₃ , T ₄
009	31	Total count	>10 ⁶	10 ⁵	10 ⁵	10 ⁵	–
		α-hemolytic streptococci count	10	30	–	10 ²	T ₁ , T ₂
010	38	Total count	>10 ⁶	10 ⁵	10 ⁵	>10 ⁶	–
		α-hemolytic streptococci count	10 ³	10 ²	10	10 ²	T ₁ , T ₂ , T ₃ , T ₄
011	30	Total count	10 ⁶	10 ⁵	10 ⁶	10 ⁶	–
		α-hemolytic streptococci count	10 ²	50	10 ²	70	T ₁ , T ₂ , T ₃ , T ₄
012	27	Total count	10 ⁵	10 ⁵	10 ⁴	10 ⁵	–
		α-hemolytic streptococci count	20	50	10	80	T ₁ , T ₂
013	23	Total count	>10 ⁶	10 ⁵	10 ⁵	10 ⁴	–
		α-hemolytic streptococci count	10 ²	5 × 10	10 ²	8 × 10	T ₁ , T ₂
014	32	Total count	>10 ⁶	10 ⁵	10 ⁵	10 ⁵	–
		α-hemolytic streptococci count	9 × 10 ³	5 × 10 ²	70	10	T ₁ , T ₂
015	43	Total count	>10 ⁶	>10 ⁶	10 ⁵	10 ⁶	–
		α-hemolytic streptococci count	–	10	80	50	–
016	42	Total count	>10 ⁶	>10 ⁶	>10 ⁶	>10 ⁶	–
		α-hemolytic streptococci count	10 ²	50	50	30	T ₁ , T ₂ , T ₃ , T ₄
017	52	Total count	10 ⁶	10 ⁶	10 ⁵	10 ⁴	–
		α-hemolytic streptococci count	–	20	10	20	T ₂ , T ₃ , T ₄
018	36	Total count	10 ⁶	10 ⁶	10 ⁵	10 ⁴	–
		α-hemolytic streptococci count	10 ²	80	10	50	T ₁ , T ₂
019	33	Total count	10 ⁶	10 ⁵	10 ⁶	10 ⁶	–
		α-hemolytic streptococci count	10 ³	10 ²	10	10	T ₁ , T ₂ , T ₃ , T ₄
020	24	Total count	10 ⁶	10 ⁵	10 ⁶	10 ⁶	–
		α-hemolytic streptococci count	10 ²	50	10 ²	70	T ₁ , T ₂ , T ₃ , T ₄

Discussion

There is great interest in the role of the microbiome in the complex equilibrium between a healthy state and progression towards disease. Many studies have addressed this role, above all in gastrointestinal-related diseases and oral pathologies, but only a few have

supported a beneficial microflora involvement in URTIs [2, 22–24].

The new approach to use “friendly bacteria”, which means to use harmless bacteria to displace pathogenic organisms—by bacterial interference—thus preventing colonization of pathogenic bacteria, is gaining ever more interest, finding applications in many fields [25]. Among studies involving upper




Fig. 2 Random amplified polymorphic DNA (RAPD) fingerprinting with OPA3 and OPA18 primers. Lane 1: Marker 1 kb; lanes 2 and 7: *S. salivarius* 24SMBc; lanes 3 and 8: patient 3 at T₁; lanes 4 and 9: patient 4 at T₁; lanes 5 and 10: patient 6 at T₃; lanes 6 and 11: patient 15 at T₃; lane 12: marker 100 bp

respiratory tract diseases, only a few have pointed out the possibility of using α -hemolytic streptococci as prophylaxis against rAOM and URTIs using a single strain such as *S. salivarius* K12 in oral tablets [26, 27] or α -hemolytic streptococci group (*S. mitis*, *S. oralis*, and *S. sanguis*) in a nasal spray [28, 29], and, more recently, by using *S. sanguinis* and *Lactobacillus rhamnosus* strains [30]. However, there is still only relatively limited clinical evidence on the role of oral probiotics on health improvement. An important aspect of this “bacteriotherapy” approach is the recolonization of the rhinopharynx with healthy flora, as the pharyngeal microbiome has an essential role in the airway linings to protect against many infections [31].

Many studies have highlighted the close correlation between the reduction of potential pathogens and the presence of commensal streptococci [28]. Evidence has shown that a healthy microbiota confers protection against URTIs and a lack or reduction of α -streptococci, especially those with antagonist activity against otopathogens, has been correlated with a higher incidence of re-infections in patients with streptococcal pharyngotonsillitis. Furthermore, it has been found that children who are prone to otitis media are colonized with a lower concentration of α -streptococci compared with those who are not prone [11]; in these cases, probiotics can confer natural protection against infections and, in some cases, become a new prophylaxis. In this context, *S. salivarius*, a non-pathogenic species and predominant colonizer of the oral microbiota, finds a wide application in the prevention of URTIs.

The current study, conducted on healthy volunteers, demonstrated that the administration of a dose of 8×10^9 CFU per day of *S. salivarius* 24SMBc [15] as a nasal spray was well

tolerated in all volunteers, and there were no side and/or undesirable effects; in addition, 95 % of volunteers were colonized by *S. salivarius* 24SMBc and 55 % remained colonized until the sixth day after the last administration, whereas low-rate staphylococcal colonization in six samples could have interfered with *S. salivarius* 24SMBc colonization.

In conclusion, the primary endpoint of our study—the nasal spray safety and human tolerability—as well as the secondary endpoint in terms of persistence of colonization, were largely achieved in all cases treated.

The application of oral probiotics is a relatively undeveloped field but is becoming an attractive approach for prevention and therapy, especially for pediatric age patients. *S. salivarius* 24SMBc possess characteristics making this strain suitable for use in bacteriotherapy.

Acknowledgments This study was supported by a project funded by the Italian Ministry of Education, University and Research (MIUR), PON_02589 and a research grant from DMG Italia. The nasal spray as a medical device was kindly provided by DMG Italia. We thank the Scientific Bureau of the University of Catania for the language support.

Conflict of interest The authors declare that there is no conflict of interest.

References

1. Lenoir-Wijnkoop I, Sanders ME, Cabana MD, Caglar E, Cothier G, Rayes N, Sherman PM, Timmeman HM, Vanechoutte M, Van Loo J, Wolvers DA (2007) Probiotic and prebiotic influence beyond the intestinal tract. *Nutr Rev* 11(65):469–489
2. Gareau MG, Sherman PM, Walker WA (2010) Probiotics and the gut microbiota in intestinal health and disease. *Nat Rev Gastroenterol Hepatol* 7(9):503–514, review
3. Ashraf R, Shah NP (2014) Immune system stimulation by probiotic microorganisms. *Crit Rev Food Sci Nutr* 54:938–956
4. Koboziev I, Reinoso Webb C, Furr KL, Grisham MB (2014) Role of the enteric microbiota in intestinal homeostasis and inflammation. *Free Radic Biol Med* 68:122–133
5. Liu S, Hu P, Du X, Zhou T, Pei X (2013) *Lactobacillus rhamnosus* GG supplementation for preventing respiratory infections in children: a meta-analysis of randomized, placebo-controlled trials. *Indian Pediatr* 50(4):377–381
6. Cohen R, Martin E, de La Rocque F, Thollot F, Pecquet S, Werner A, Boucherat M, Varon E, Bingen E, Levy C (2013) Probiotics and prebiotics in preventing episodes of acute otitis media in high-risk children: a randomized, double-blind, placebo-controlled study. *Pediatr Infect Dis J* 32(8):810–814
7. Hatakka K, Blomgren K, Pohjavuori S, Kaijalainen T, Poussa T, Leinonen M, Korpela R, Pitkäranta A (2007) Treatment of acute otitis media with probiotics in otitis-prone children a double-blind, placebo-controlled randomised study. *Clin Nutr* 26(3):314–321
8. Wescombe PA, Hale JD, Heng NC, Tagg JR (2012) Developing oral probiotics from *Streptococcus salivarius*. *Future Microbiol* 7: 1355–1371
9. Monasta L, Ronfani L, Marchetti F, Montico M, Vecchi Brumatti L, Bavcar A, Grasso D, Barbiero C, Tamburini G (2012) Burden of disease caused by otitis media: systematic review and global estimates. *PLoS One* 7:e36226

10. Lieberthal AS, Carroll AE, Chonmaitree T, Ganiats TG, Hoberman A, Jackson MA, Joffe MD, Miller DT, Rosenfeld RM, Sevilla XD, Schwartz RH, Thomas PA, Tunkel DE; American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media (2013) The diagnosis and management of acute otitis media. *Pediatrics* 131:e964–e999
11. Marchisio P, Claut L, Rognoni A, Esposito S, Passali D, Bellussi L, Drago L, Pozzi G, Mannelli S, Schito G, Principi N (2003) Differences in nasopharyngeal bacterial flora in children with nonsevere recurrent acute otitis media and chronic otitis media with effusion: implications for management. *Pediatr Infect Dis J* 22:262–268
12. John M, Dunne EM, Licciardi PV, Satzke C, Wijburg O, Robins-Browne RM, O'Leary S (2013) Otitis media among high-risk populations: can probiotics inhibit *Streptococcus pneumoniae* colonisation and the risk of disease? *Eur J Clin Microbiol Infect Dis* 32(9): 1101–1110, review
13. Tagg JR (2004) Prevention of streptococcal pharyngitis by anti-*Streptococcus pyogenes* bacteriocin-like inhibitory substances (BLIS) produced by *Streptococcus salivarius*. *Indian J Med Res* 119(Suppl):13–16
14. Burton JP, Chilcott CN, Moore CJ, Speiser G, Tagg JR (2006) A preliminary study of the effect of probiotic *Streptococcus salivarius* K12 on oral malodour parameters. *J Appl Microbiol* 100(4): 754–764
15. Santagati M, Scillato M, Patané F, Aiello C, Stefani S (2012) Bacteriocin-producing oral streptococci and inhibition of respiratory pathogens. *FEMS Immunol Med Microbiol* 65(1):23–31
16. Stol K, Verhaegh SJ, Graamans K, Engel JA, Sturm PD, Melchers WJ, Meis JF, Warris A, Hays JP, Hermans PW (2013) Microbial profiling does not differentiate between childhood recurrent acute otitis media and chronic otitis media with effusion. *Int J Pediatr Otorhinolaryngol* 77(4):488–493
17. Céline J, Södermark L, Hjalmarson O (2014) Adherence to treatment guidelines for acute otitis media in children. The necessity of an effective strategy of guideline implementation. *Int J Pediatr Otorhinolaryngol* 78(7):1128–1132
18. Tagg JR, Bannister LV (1979) "Fingerprinting" beta-haemolytic streptococci by their production of and sensitivity to bacteriocine-like inhibitors. *J Med Microbiol* 12:397–411
19. Truong TL, Ménard C, Mouton C, Trahan L (2000) Identification of mutans and other oral streptococci by random amplified polymorphic DNA analysis. *J Med Microbiol* 49:63–71
20. Conticello S, Saita V, La Mantia I, Ferlito S (1989) Endoscopy of the eustachian tube: use of the fiberscope and the telescope. *Arch Otorhinolaryngol* 246:256–258, Springer-Verlag Ed
21. Serra A, Grillo C, La Mantia I, Cipri R, Vancheri M, Saita V (1992) Naso-pharyngo-laryngoscopie et rhinomanométrie avec endoscope flexible dans l'étude de l'hypertrophie adénoïde. *Acta Endoscopica Belg* 22:381–384
22. Human Microbiome Project Consortium (2012) Structure, function and diversity of the healthy human microbiome. *Nature* 486: 207–214
23. Aas JA, Paster BJ, Stokes LN, Olsen I, Dewhirst FE (2005) Defining the normal bacterial flora of the oral cavity. *J Clin Microbiol* 43(11):5721–5732
24. Socol CR, Porto de Souza Vandenberghe L, Spier MR, Pedroni Medeiros AB, Yamagishi CT, De Dea Lindner J, Pandey A, Thomaz-Socol V (2010) The potential of probiotics: a review. *Food Technol Biotech* 48(4):413–434
25. Caglar E, Kargul B, Tanboga I (2005) Bacteriotherapy and probiotics' role on oral health. *Oral Dis* 11(3):131–137
26. Di Pierro F, Colombo M, Zanvit A, Risso P, Rottoli AS (2014) Use of *Streptococcus salivarius* K12 in the prevention of streptococcal and viral pharyngotonsillitis in children. *Drug Healthc Patient Saf* 6:15–20
27. Walls T, Power D, Tagg J (2003) Bacteriocin-like inhibitory substance (BLIS) production by the normal flora of the nasopharynx: potential to protect against otitis media? *J Med Microbiol* 52(Pt 9): 829–833
28. Roos K, Håkansson EG, Holm S (2001) Effect of recolonisation with "interfering" alpha streptococci on recurrences of acute and secretory otitis media in children: randomised placebo controlled trial. *BMJ* 322(7280):210–212
29. Tano K, Grahn Håkansson E, Holm SE, Hellström S (2002) A nasal spray with alpha-haemolytic streptococci as long term prophylaxis against recurrent otitis media. *Int J Pediatr Otorhinolaryngol* 62(1): 17–23
30. Skovbjerg S, Roos K, Holm SE, Grahn Håkansson E, Nowrouzian F, Ivarsson M, Adlerberth I, Wold AE (2009) Spray bacteriotherapy decreases middle ear fluid in children with secretory otitis media. *Arch Dis Child* 94(2):92–98
31. Gao Z, Kang Y, Yu J, Ren L (2014) Human pharyngeal microbiome may play a protective role in respiratory tract infections. *Genomics Proteomics Bioinformatics* 12(3):144–150